

1. **Cerami A**, Reich E, Ward DC, Goldberg IH. (1967). The interaction of actinomycin with DNA: Requirement for the 2-amino group of purines. *Proc Natl Acad Sci USA* 57:1036-1042.
2. Beers W, **Cerami A**, Reich E. (1967). An experimental model for internal denaturation of linear DNA molecules. *Proc Natl Acad Sci USA* 58:1624-1631.
3. Reich E, **Cerami A**, Ward DC. (1967). Actinomycin. In *Antibiotics-Mechanism of Action*. Gottlieb D, Shaw PD (eds). Heidelberg: Springer-Verlag. Vol I:714-725.
4. Klett RP, **Cerami A**, Reich E. (1968). Exonuclease VI, a new nuclease activity associated with *E. coli* DNA polymerase. *Proc Natl Acad Sci USA* 60:943-950.
5. **Cerami A**. (1969). Selective adsorption of nonhelical polynucleotides to an organomercurial sephadex. *J Biol Chem* 244(1):221-222.
6. Ward DC, **Cerami A**, Reich E, Acs G, Altwerger L. (1969). Biochemical studies of the nucleoside analogue, formycin. *J Biol Chem* 244:3243-3250.
7. **Cerami A**, Manning JM. (1971). Potassium cyanate as an inhibitor of the sickling of erythrocytes *in vitro*. *Proc Natl Acad Sci USA* 68:1180-1183.
8. Gillette PN, Manning JM, **Cerami A**. (1971). Increased survival of sickle cell erythrocytes after treatment *in vitro* with sodium cyanate. *Proc Natl Acad Sci USA* 68:2791-2793.
9. de Furia FG, Miller D, **Cerami A**, Manning JM. (1972). The effects of cyanate *in vitro* on red blood cell metabolism and function in sickle cell anemia. *J Clin Invest* 51:566-574.
10. **Cerami A**. (1972). Cyanate as an inhibitor of red cell sickling. *N Engl J Med* 287:807-812.
11. Manning JM, **Cerami A**, Gillette PN, de Furia FG, Miller DR. (1972). Chemical and biological aspects of the inhibition of red blood cell sickling by cyanate. In *Hemoglobin and Red Cell Structure and Function*. Brewer GJ (ed). New York: Plenum. p 253-260.
12. Gillette PN, Peterson CM, Manning JM, **Cerami A**. (1972). Preliminary clinical trials with cyanate. In *Hemoglobin and Red Cell Structure and Function*. Brewer GJ (ed). New York: Plenum. p 261-278.
13. **Cerami A**, Allen TA, Graziano JH, de Furia FG, Manning JM, Gillette PN. (1973). Pharmacology of cyanate I. General effects on experimental animals. *J Pharmacol Exp Therap* 185:653-666.

14. **Cerami A**, Manning JM, Gillette PN, de Furia FG, Miller DR, Graziano JH, Peterson M. (1973). Effect of cyanate on red blood cell sickling. *Fed Proc* 32:16681672.
15. Friedman PA, **Cerami A**. (1973). Actinomycin. In *Cancer Medicine*. Holland JF, Frei E III (eds). Philadelphia: Lea and Febiger. p 835839.
16. Graziano JH, Thornton YS, Leong JK, **Cerami A**. (1973). Pharmacology of cyanate II. Effects on the endocrine system. *J Pharmacol Exp Therap* 185:667675.
17. Manning JM, Lee CK, **Cerami A**, Gillette PN. (1973). Gas chromatographic determination of the carbamylation of hemoglobin S by cyanate. *J Lab Clin Med* 81:941945.
18. Graziano JH, de Furia FG, **Cerami A**. (1973). The use of ¹⁴Ccyanate as a method for determining erythrocyte survival. *Proc Soc Exp Biol Med* 144:326328.
19. Manning JM, **Cerami A**, Gillette PN, de Furia FG, Miller D. (1973). Cyanate inhibition of red blood cell sickling. In *Sickle Cell Disease*. Abramson H, Bertles JF, Wethers DL (eds). St Louis: Mosby. p 177188.
20. de Furia FG, **Cerami A**, Bunn HF, Lu YS, Peterson CM. (1973). The effect of aspirin on sickling and oxygen affinity of erythrocytes. *Proc Natl Acad Sci USA* 70:37073710.
21. Bridges KR, de Furia FG, Lu YS, Peterson CM, Schmidt GJ, Jensen M, **Cerami A**, Bunn HF. (1974). The acetylation of hemoglobin by aspirin. In *DHEW Publications, Volume 75*. Bethesda: National Institutes of Health. p 185186.
22. Gillette PN, Peterson CM, Lu YS, **Cerami A**. (1974). Sodium cyanate as a potential treatment for sickle cell disease. *N Engl J Med* 290:654660.
23. Manning JM, **Cerami A**, Gillette PN, de Furia FG, Miller DR. (1974). Biochemical and physiological properties of carbamylated hemoglobin. *Adv Enzymol* 40:127.
24. Manning JM, **Cerami A**, Gillette PN, de Furia FG, Miller DR, Peterson CM. (1974). Inhibition of red blood cell sickling by cyanate. *Ann Okla Acad Sci* 4:4755.
25. **Cerami A**. (1974). Recent developments in the chemistry and therapy of sickle cell anemia. *PAABS Revista* 3:707713.
26. Peterson CM, **Cerami A**. (1974). Sodium cyanate and sickle cell disease: Efficacy vs. toxicity. In *DHEW Publications, Volume 75*. Bethesda: National Institutes of Health. p 3738.

27. Peterson CM, Lu YS, Herbert JT, **Cerami A**, Gillette PN. (1974). Studies with intravenous sodium cyanate in patients with sickle cell disease. *J Pharmacol Exp Therap* 189:577584.
28. Graziano JH, Grady RW, **Cerami A**. (1974). The identification of 2,3dihydroxybenzoic acid as a potentially useful ironchelating drug. *J Pharmacol Exp Therap* 190:570575.
29. Leong JK, Grady RW, Herbert J, Graziano JH, **Cerami A**, Judge M, Quartermain D. (1974). Pharmacology of cyanate III. Effects on the central nervous system. *J Pharmacol Exp Therap* 191: 6067.
30. Peterson CM, **Cerami A**. (1974). Therapy of sickle cell disease: an approach with sodium cyanate. *Sem Hematol* 11:569576.
31. **Cerami A**. (1974). Review of the development of cyanate as a drug in the treatment of sickle cell anemia. *Ann NY Acad Sci* 241:538544.
32. Peterson CM, Tsairis P, Ohnishi A, Lu YS, Grady R, **Cerami A**, Cyck PJ. (1974). Sodium cyanate induced polyneuropathy in patients with sickle cell disease. *Ann Intern Med* 81:152158.
33. Peterson CM, **Cerami A**. (1975). "Orphandrug" development whose responsibility. *N Engl J Med* 292:162.
34. **Cerami A**, Peterson CM. (1975). Cyanate and sickle cell disease. *Sci Am* 232:4450.
35. Bridges KR, Schmidt GJ, Jensen M, **Cerami A**, Bunn HF. (1975). The acetylation of hemoglobin by aspirin. *In vitro* and *in vivo*. *J Clin Invest* 56: 201207.
36. Koenig RJ, **Cerami A**. (1975). Synthesis of hemoglobin A1C in normal and diabetic mice: Potential model of basement membrane thickening. *Proc Natl Acad Sci USA* 72: 36873691.
37. Peterson CM, Graziano JH, de Ciutiis A, Grady RW, **Cerami A**, Worwood M, Jacobs A. (1975). Iron metabolism, sickle cell disease and response to cyanate. *Blood* 46: 583590.
38. **Cerami A**, Graziano JH, Grady RW, Peterson CM. (1976). The development of new iron chelating drugs. In *Development of Iron Chelators for Clinical Use*. Anderson WF, Hiller MC (eds). Bethesda: NIH. p 261273.
39. Bergsma D, **Cerami A**, Peterson CM, Graziano JH (eds). (1976). In *Iron Metabolism and Thalassemia*. Birth Defects: Original Article Series, Volume XII, Number 8. New York: Liss.

40. **Cerami A.** (1976). The development of new drugs for genetic diseases. In Stadler Symposium, Volume 8. Columbia: University of Missouri. p 171-180.
41. Koenig RJ, Araujo DC, **Cerami A.** (1976). Increased hemoglobin A_{1c} in diabetic mice Diabetes 25: 15.
42. Grady RW, Graziano JH, Akers HA, **Cerami A.** (1976). The development of new ironchelating drugs. J Pharmacol Exp Therap 196: 478485.
43. Graziano JH, Miller DR, Grady RW, **Cerami A.** (1976). Inhibition of membrane peroxidation in thalassaemic erythrocytes by 2,3dihydroxybenzoic acid. Br J Haematol 32: 351356.
44. Koenig RJ, Peterson CM, Kilo C, **Cerami A.**, Williamson JR. (1976). Hemoglobin A_{1c} as an indicator of the degree of glucose intolerance in diabetes. Diabetes 25: 230232.
45. **Cerami A.** (1976). Editorial: "Propper" use of desferrioxamine. N Engl J Med 294: 14561457.
46. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, **Cerami A.** (1976). Correlation of glucose regulation and hemoglobin A_{1c} in diabetes mellitus. N Engl J Med 295: 417420.
47. Peterson CM, Graziano JH, Grady RW, Jones RL, Vlassara HV, Canale VC, Miller DR, **Cerami A.** (1976). Chelation studies with 2,3dihydroxybenzoic acid in patients with β thalassaemia major. Br J Haematol 33: 477485.
48. White GP, Jacobs A, Grady RW, **Cerami A.** (1976). The use of Chang cells cultured *in vitro* to evaluate potential iron chelating drugs. Br J Haematol 33: 487495.
49. White GP, Jacobs A, Grady RW, **Cerami A.** (1976). The effect of chelating agents on iron mobilization in Chang cell cultures. Blood 48: 923929.
50. **Cerami A.**, Grady RW, Peterson CM. (1977). New iron chelators. In Chelation Therapy in Chronic Iron Overload. Zaino EC, Roberts RH (eds). Miami: Symposia Specialists. p 3752.
51. **Cerami A.**, Grady RW, Peterson CM, Jones RL, Graziano JH. (1977). The development of new iron chelating drugs for the treatment of patients with thalassemia. In Proteins of Iron Metabolism. Brown EB (ed). New York: Grune and Stratton. p 439444.
52. Graziano JH, **Cerami A.** (1977). Chelation therapy for the treatment of thalassemia. Sem Hematol 14: 127134.

53. TellezNagel I, Korthals JK, Vlassara H, **Cerami A.** (1977). An ultrastructural study of chronic sodium cyanateinduced neuropathy. *J Neuropathol Exp Neurol* 36: 351363.
54. Jones RL, Peterson CM, Grady RW, Kumbaraci T, **Cerami A,** Graziano JH. (1977). Effect of iron chelators and iron overload on salmonella infection. *Nature* 267: 6365.
55. Koenig RJ, Blobstein SH, **Cerami A.** (1977). Structure of carbohydrate of hemoglobin A1C. *J Biol Chem* 252: 29922997.
56. Peterson CM, Koenig RJ, Jones RL, Saudek CD, **Cerami A.** (1977). Correlation of serum triglyceride levels and hemoglobin A1C concentrations in diabetes mellitus. *Diabetes* 26: 507509.
57. Stevens VJ, Vlassara H, Abati A, **Cerami A.** (1977). Nonenzymatic glycosylation of hemoglobin. *J Biol Chem* 252: 29983002.
58. Meshnick SR, Chang KP, **Cerami A.** (1977). Heme lysis of the bloodstream forms of *Trypanosoma brucei*. *Biochem Pharmacol* 26: 19231928.
59. Peterson CM, Grady RW, Jones RL, **Cerami A,** Graziano JH, Markenson AL, Lavi U, Canale V, Gray GF, Miller DR. (1977). 3DHB ineffective in treatment of iron overload. *N Engl J Med* 297: 1404.
60. Blobstein SH, Grady RW, Meshnick SR, **Cerami A.** (1978). Hydroxamic acid oxidation pharmacological considerations. *Biochem Pharmacol* 27: 29392945.
61. **Cerami A,** Koenig RJ. (1978). Hemoglobin A1C as a model for the development of the sequelae of diabetes mellitus. *TIBS* 3: 7375.
62. **Cerami A,** Koenig RJ, Peterson CM. (1978). Hemoglobin A1C and diabetes mellitus. *Br J Haematol* 38: 13.
63. **Cerami A,** Koenig RJ, Peterson CM, Stevens VJ. (1978). The formation of HBA1C as a biochemical model for the sequelae of diabetes. In *The Red Cell*. New York: Liss. p 3340.
64. Grady RW, **Cerami A.** (1978). The current status of iron chelation therapy. *Ann Rep Med Chem* 13: 219226.
65. Javid J, Pettis PK, Koenig RJ, **Cerami A.** (1978). Immunologic characterization and quantification of haemoglobin A1C . *Br J Haematol* 38: 329337.

66. Grady RW, Graziano JH, White GP, Jacobs A, **Cerami A.** (1978). The development of new ironchelating drugs. II. *J Pharmacol Exp Therap* 205: 757765.
67. Stevens VJ, Rouzer CA, Monnier VM, **Cerami A.** (1978). Diabetic cataract formation: potential role of glycosylation of lens crystallins. *Proc Natl Acad Sci USA* 75: 29182922.
68. Hershko C, Grady RW, **Cerami A.** (1978). Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron metabolism. *J Lab Clin Med* 92: 144151.
69. Meshnick SR, Blobstein SH, Grady RW, **Cerami A.** (1978). An approach to the development of new drugs for African trypanosomiasis. *J Exp Med* 148: 569579.
70. **Cerami A.** (1978). Drug development for "orphan" diseases. *Amer J Med* 65: 407408.
71. Meshnick SR, Grady RW, Blobstein SH, **Cerami A.** (1978). Porphyrininduced lysis of *Trypanosoma brucei*: a role for zinc. *J Pharmacol Exp Therap* 207: 10411050.
72. **Cerami A.** (1979). Orphan diseases. *The Sciences*. February: 2225.
73. Koenig RJ, **Cerami A.** (1979). Glycohemoglobins in the adult erythrocyte. *Curr Top Hematol* 2: 5973.
74. Koenig RJ, **Cerami A.** (1979). Nonenzymatic glycosylation. *Ann Rep Med Chem* 14: 261267.
75. Peterson CM, Graziano JH, Grady RW, Jones RL, Markenson A, Lavi U, Canale V, Gray GF, **Cerami A**, Miller DR. (1979). Chelation therapy in β thalassemia major: A oneyear double blind study of 2,3-dihydroxybenzoic acid. *Exp Hematol* 17: 7480.
76. Kokkini G, Bhargava KK, Benjamin LJ, Grady RW, Peterson CM, **Cerami A.** (1979). The design of new antisickling drugs. In *Development of Therapeutic Agents for Sickle Cell Disease*. Beuzard J, Hercules J (eds). INSERM Symposium No Rosa. Amsterdam: NorthHolland. p 111117.
77. **Cerami A**, Stevens VJ, Monnier VM. (1979). Role of nonenzymatic glycosylation in the development of the sequelae of diabetes mellitus. *Metabolism* 28: 431437.
78. Grady RW, Peterson CM, Jones RL, Graziano JH, Bhargava KK, Berdoukas VA, Kokkini G, Loukopoulos D, **Cerami A.** (1979). Rhodotorulic acid - investigation of its potential as an ironchelating drug. *J Pharmacol Exp Therap* 209: 342348.

79. Tellez I, Johnson D, Nagel RL, **Cerami A.** (1979). Neurotoxicity of sodium cyanate. New pathological and ultrastructural observations in *Maccaca nemestrina*. *Acta Neuropathol* 47: 7579.
80. Cohn JA, **Cerami A.** (1979). The influence of genetic background on the susceptibility of mice to diabetes induced by alloxan and on recovery from alloxan diabetes. *Diabetologia* 17: 187191.
81. Monnier VM, Stevens VJ, **Cerami A.** (1979). Nonenzymatic glycosylation, sulfhydryl oxidation and aggregation of lens proteins in experimental sugar cataracts. *J Exp Med* 150: 10981107.
82. Brownlee M, **Cerami A.** (1979). A glucosecontrolled insulindelivery system: semisynthetic insulin bound to lectin. *Science* 206: 11901191.
83. **Cerami A,** Meshnick SR. (1979). Rational development of new drugs for trypanosomiasis. In *Pharmaceuticals for the Developing Countries*. Simon HJ (ed). Washington: National Academy of Sciences. p 312317.
84. **Cerami A,** Grady RW, Peterson CM, Bhargava KK. (1980). The status of new iron chelators. *Ann NY Acad Sci* 344: 425435.
85. Koenig RJ, Stevens VJ, **Cerami A.** (1980). Nonenzymatic glycosylation and browning of hemoglobin and other body proteins. *J Appl Biochem* 2: 431438.
86. Monnier VM, Stevens VJ, **Cerami A.** (1980). Nonenzymatic glycosylation of hemoglobin and lens crystallins. In *Red Blood Cell and Lens Metabolism*. Srivastava SK (ed). Amsterdam: Elsevier North Holland. p 463474.
87. Jones RL, Peterson CM, Grady RW, **Cerami A.** (1980). A low molecular weight ironbinding factor from mammalian tissue that potentiates bacterial growth. *J Exp Med* 151: 418428.
88. Peterson CM, Jovanovic LB, Brownlee M, Jones RL, **Cerami A.** (1980). Closing the loop: practical and theoretical. *Diabetes Care* 3: 318321.
89. Chang LMS, Cheriathundam E, Mahoney EM, **Cerami A.** (1980). DNA polymerases in parasitic protozoans differ from host enzymes. *Science* 208: 510511.
90. Ganeshaguru K, Hoffbrand AV, Grady RW, **Cerami A.** (1980). Effect of various iron chelating agents on DNA synthesis in human cells. *Biochem Pharmacol* 29: 12751279.
91. Bhargava KK, Grady RW, **Cerami A.** (1980). New compounds: N1,N8bis(2,3dihydroxy benzoyl)spermidine and analogs as potential iron chelating drugs. *J Pharm Sci* 69: 986989.

92. Tabachnik NF, Peterson CM, **Cerami A.** (1980). Studies on the reduction of sputum viscosity in cystic fibrosis using an orally absorbed protected thiol. *J Pharmacol Exp Therap* 214: 246249.
93. Kokkini G, Stevens VJ, Peterson CM, **Cerami A.** (1980). Modification of hemoglobin by ninhydrin. *Blood* 56: 701705.
94. Rouzer CA, **Cerami A.** (1980). Hypertriglyceridemia associated with *trypanosoma brucei brucei* infection in rabbits: Role of defective triglyceride removal. *Mol Biochem Parasitol* 2: 3138.
95. Brownlee M, Vlassara H, **Cerami A.** (1980). Measurement of glycosylated amino acids and peptides from urine of diabetic patients using affinity chromatography. *Diabetes* 29: 10441047.
96. Koenig RJ, **Cerami A.** (1980). Hemoglobin A1C and diabetes mellitus. *Ann Rev Med* 31: 2934.
97. Stevens VJ, Monnier VM, **Cerami A.** (1980). Hemoglobin glycosylation as a model for modification of other proteins. *Texas Reports on Biology and Medicine* 40: 387396.
98. Brownlee M, **Cerami A.** (1981). The biochemistry of the complications of diabetes mellitus. *Ann Rev Biochem* 50: 385432.
99. Monnier VM, **Cerami A.** (1981). Nonenzymatic browning *in vivo*: possible process for aging of longlived proteins. *Science* 211: 491494.
100. Stevens VJ, Fantl WJ, Newman CB, Sims RV, **Cerami A,** Peterson CM. (1981). Acetaldehyde adducts with hemoglobin. *J Clin Invest* 67:361369.
101. Arrick BA, Griffith OW, **Cerami A.** (1981). Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis. *J Exp Med* 153: 720725.
102. Thornton YS, **Cerami A.** (1981). Sickle cell crisis during pregnancy in a patient with hemoglobin SD disease. *Am J Obstet Gynecol* 139: 739740.
103. Monnier VM, Stevens VJ, **Cerami A.** (1981). Maillard reactions involving proteins and carbohydrates *in vivo*: relevance to diabetes mellitus and aging. *Prog Fd Nutr Sci* 5: 315327.
104. Tabachnik NF, Blackburn P, **Cerami A.** (1981). Biochemical and rheological characterization of sputum mucins from a patient with cystic fibrosis. *J Biol Chem* 256: 71617165.
105. Vlassara H, Brownlee M, **Cerami A.** (1981). Nonenzymatic glycosylation of peripheral nerve

protein in diabetes mellitus. Proc Natl Acad Sci USA 78: 51905192.

106. Kawakami M, **Cerami A.** (1981). Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med 154: 631639.

107. **Cerami A.** (1981). Nonenzymatic glycosylation and browning of the lens. In New Directions in Ophthalmic Research. Sears M (ed). New Haven: Yale University. p 7788.

108. Tabachnik NF, Blackburn P, Peterson CM, **Cerami A.** (1982). Protein binding of N2mercaptoethyl-1,3diaminopropane via mixed disulfide formation after oral administration of WR 2721. J Pharmacol Exp Therap 220: 243246.

109. Kawakami M, Pekala PH, Lane MD, **Cerami A.** (1982). Lipoprotein lipase suppression of 3T3L1 cells by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci USA 79: 912916.

110. Ulrich PC, Grady RW, **Cerami A.** (1982). The trypanocidal activity of various aromatic bisguanylhydrazones *in vivo*. Drug Develop Res 2: 219228.

111. Ulrich PC, **Cerami A.** (1982). Potential antitrypanosomal agents. 1,N2disubstituted 2amino5hydroxy4methylnaphtho[1,2d]thiazolium salts and related compounds. J Med Chem 25: 654657.

112. Bucala R, Fishman J, **Cerami A.** (1982). Formation of covalent adducts between cortisol and 16 alphahydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus. Proc Natl Acad Sci USA 79: 33203324.

113. Monnier VM, **Cerami A.** (1982). Nonenzymatic glycosylation and browning in diabetes and aging. Studies on lens proteins. Diabetes 31 Suppl 3: 5763.

114. Monnier VM, **Cerami A.** (1982). Nonenzymatic glycosylation and browning of proteins in diabetes. In Clinics in Endocrinology and Metabolism, Volume 11. Philadelphia: Saunders. p 431452.

115. Vlassara H, Brownlee M, **Cerami A.** (1982). Assessment of diabetic control by measurement of urinary glycopeptides. Diabetologia 23: 252254.

116. **Cerami A.** (1982). Advances in medical science. In On the Brink of Tomorrow: Frontiers of Science. Crump DJ (ed). Washington: National Geographic Society. p 148171.

117. Le Trang N, Meshnick SR, Kitchener K, Eaton JW, **Cerami A.** (1983). Iron-containing superoxide dismutase from *Crithidia fasciculata*: purification, characterization and similarity to leishmanial and

trypanosomal enzymes. J Biol Chem 258: 125130.

118. Sassa S, Kawakami M, **Cerami A.** (1983). Inhibition of the growth and differentiation of erythroid precursor cells by an endotoxin-induced mediator from peritoneal macrophages. Proc Natl Acad Sci USA 80: 17171720.

119. Pekala P, Kawakami M, Vine W, Lane MD, **Cerami A.** (1983). Studies of insulin resistance in adipocytes induced by macrophage mediator. J Exp Med 157: 13601365.

120. Hotez PJ, **Cerami A.** (1983). Secretion of a proteolytic anticoagulant by *Ancylostoma* hookworms. J Exp Med 157: 15941603.

121. Bucala R, Kawakami M, **Cerami A.** (1983). Cytotoxicity of a perfluorocarbon blood substitute to macrophages *in vitro*. Science. 220: 965967.

122. Bhargava KK, Sarin VK, Le Trang N, **Cerami A,** Merrifield RB. (1983). Synthesis of a cyclic analogue of oxidized glutathione by an intersite reaction in a swollen polymer network. J Am Chem Soc 105: 32473251.

123. Pekala PH, Kawakami M, Angus CW, Lane MD, **Cerami A.** (1983). Selective inhibition of synthesis of enzymes for de novo fatty acid biosynthesis by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci USA 80: 27432747.

124. Brownlee M, **Cerami A.** (1983). Glycosylated insulin complexed to concanavalin A: biochemical basis for a closed-loop insulin delivery system. Diabetes 32: 499504.

125. Monnier VM, **Cerami A.** (1983). Nonenzymatic glycosylation and browning of proteins *in vivo*. In Maillard Reaction in Food and Nutrition. Waller GA (ed). Washington DC: American Chemical Society. p 431449.

126. Vlassara H, Brownlee M, **Cerami A.** (1983). Excessive nonenzymatic glycosylation of peripheral and central nervous system myelin components in diabetic rats. Diabetes 32: 670674.

127. Brownlee M, Vlassara H, **Cerami A.** (1983). Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes 32: 680684.

128. Jones RL, **Cerami A.** (1983). Nonenzymatic glycosylation of proteins in diabetes mellitus. In Recent Advances in Diabetes. Nattrass M, Santiago JV (eds). London: Pitman. p 173180.

129. Pascal RA Jr, Le Trang N, **Cerami A,** Walsh C. (1983). Purification and properties of

dihydroorotate oxidase from *Crithidia fasciculata* and *Trypanosoma brucei*. *Biochemistry* 22: 171178.

130. Bhargava KK, Le Trang N, **Cerami A**, Eaton JW. (1983). Effect of arsenical drugs on glutathione metabolism of *Litomosoides carinii*. *Mol Biochem Parasitol* 9: 2935.

131. Le Trang N, Bhargava KK, **Cerami A**. (1983). Purification of glutathione reductase from gerbil liver in two steps. *Anal Biochem* 133: 9499.

132. Monnier VM, **Cerami A**. (1983). Detection of nonenzymatic browning products in the human lens. *Biochim Biophys Acta* 760: 97103.

133. Castells S, Smith S, Walberg J, **Cerami A**. (1983). Genetic influences on pancreas transplantation. *Transplantation* 36: 457459.

134. Brownlee M, Pongor S, **Cerami A**. (1983). Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen: role in the *in situ* formation of immune complexes. *J Exp Med* 158: 17391744.

135. Bucala R, **Cerami A**. (1983). Characterization of antisera to the addition product formed by the nonenzymatic reaction of 16ahydroxyestrone with albumin. *Molec Immunol* 20: 12891292.

136. Pongor S, Brownlee M, **Cerami A**. (1983). Preparation of highpotency nonaggregating insulins using a novel sulfation procedure. *Diabetes* 32: 10871091.

137. Meshnick SR, Le Trang N, Kitchener K, **Cerami A**, Eaton J. (1983). Ironcontaining superoxide dismutases in trypanosomatids. In *Oxy Radicals and their Scavenger Systems. Molecular Aspects. Volume I*. Cohen G, Greenwald RA (eds). New York: Elsevier. p 348352.

138. Sarin VK, Bhargava KK, **Cerami A**, Merrifield RB. (1983). Properties of swollen polymer networks. Intersite reactions: synthesis of a cyclic analog of oxidized glutathione. In *Proceedings of the Eighth American Peptide Symposium*. p 9598.

139. Ulrich P, **Cerami A**. (1984). Trypanocidal 1,3arylene diketone bis (guanylylhydrazones). Structureactivity relationships among substituted and heterocyclic analogues. *J Med Chem* 27: 3540.

140. Bucala R, Model P, **Cerami A**. (1984). Modification of DNA by reducing sugars: A possible mechanism for nucleic acid aging and agerelated dysfunction in gene expression. *Proc Natl Acad Sci USA* 81: 105109.

141. Kohn RR, **Cerami A**, Monnier VM. (1984). Collagen aging *in vitro* by nonenzymatic glycosylation

and browning. *Diabetes* 33: 5759.

142. Brownlee M, Vlassara H, **Cerami A**, Li J, Martin T, McAdam KPW. (1984). Association of insulin pump therapy with raised serum amyloid A in Type I diabetes mellitus. *Lancet* 1: 411413.

143. Monnier VM, Kohn RR, **Cerami A**. (1984). Accelerated age-related browning of human collagen in diabetes mellitus. *Proc Natl Acad Sci USA* 81: 583587.

144. **Cerami A**. (1984). Materials which promote and inhibit the biosynthesis of cachectin, a macrophage protein which induces catabolic state: a review. In *Mechanism of Drug Action*. Singer TP (ed). New York: Academic. p 175186.

145. Meshnick SR, **Cerami A**. (1984). Host-parasite interface: biochemistry. In *Tropical and Geographical Medicine*. Warren K, Mahmoud A (eds). New York: McGrawHill. p 119124.

146. Pongor S, Ulrich PC, Bencsath FA, **Cerami A**. (1984). Aging of proteins: Isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. *Proc Natl Acad Sci USA* 81: 26842688.

147. Bucala R, Fishman J, **Cerami A**. (1984). The reaction of 16ahydroxyestrone with erythrocytes *in vitro* and *in vivo*. *Eur J Biochem* 140: 593598.

148. Hotez PJ, Le Trang N, Fairlamb A, **Cerami A**. (1984). Lipoprotein lipase suppression in 3T3L1 cells by a haematoprotzoan-induced mediator from peritoneal exudate cells. *Parasite Immunol* 6: 203209.

149. Vlassara H, Brownlee M, **Cerami A**. (1984). Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts. *J Exp Med* 160: 197207.

150. Brownlee M, Vlassara H, **Cerami A**. (1984). Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation: possible role in fibrin deposition in diabetes. *Diabetes* 32: 532535.

151. Manabe S, Bucala R, **Cerami A**. (1984). Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. *J Clin Invest* 4: 18031810.

152. Brownlee M, Vlassara H, **Cerami A**. (1984). Nonenzymatic glycosylation and the pathogenesis of diabetic complications. *Ann Intern Med* 101: 527537.

153. Grady RW, Blobstein SH, Meshnick SR, Ulrich PC, **Cerami A**, Amirmoazzami J, Hodnett EM. (1984). The *in vitro* trypanocidal activity of Nsubstituted pbenzoquinone imines: assessment of biochemical structureactivity relationships using the Hansch approach. *J Cell Biochem* 25: 1529.
154. Kawakami M, Ikeda Y, Le Trang N, Vine W, **Cerami A**. (1984). Studies of conditions and agents that stimulate and inhibit the production of cachectin by macrophages. In *Proceedings of IUPHAR*, Volume 2. Paton W (ed). London: MacMillan. p 377384.
155. Pekala PH, Price SR, Horn CA, Hom BE, Moss J, **Cerami A**. (1984). Model for cachexia in chronic disease: secretory products of endotoxin-stimulated macrophages induce a catabolic state in 3T3L1 adipocytes. In *Transactions of the Association of American Physicians*, Volume XCVII. p 251259.
156. Mahoney JR Jr, Beutler BA, Le Trang N, Vine W, Ikeda Y, Kawakami M, **Cerami A**. (1985). Lipopolysaccharidetreated RAW 264.7 cells produce a mediator which inhibits lipoprotein lipase in 3T3L1 cells. *J Immunol* 134: 16731675.
157. Fairlamb AH, Blackburn P, Ulrich P, Chait BT, **Cerami A**. (1985). Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. *Science* 227: 14851487.
158. Fairlamb AH, **Cerami A**. (1985). Identification of a novel thiolcontaining cofactor essential for glutathione reductase enzyme activity in trypanosomatids. *Mol Biochem Parasitol* 14: 187198.
159. Beutler B, Mahoney J, Le Trang N, Pekala P, **Cerami A**. (1985). Purification of cachectin, a lipoprotein lipasesuppressing hormone secreted by endotoxininduced RAW 264.7 cells. *J Exp Med* 161: 984995.
160. Bucala R, Lahita RG, Fishman J, **Cerami A**. (1985). Increased levels of 16ahydroxyestronemodified proteins in pregnancy and in systemic lupus erythematosus. *J Clin Endocrinol Metab* 60: 841847.
161. Pongor S, Brownlee M, **Cerami A**. (1985). Carbodiimidemediated Osulfation of hydroxyamino acids and peptides: A reaction suitable for radiolabeling. *Arch Biochem Biophys* 238: 458463.
162. Hotez PJ, Le Trang N, McKerrow JH, **Cerami A**. (1985). Isolation and characterization of a proteolytic enzyme from the adult hookworm *Ancylostoma caninum*. *J Biol Chem* 260: 73437348.
163. Vlassara H, Brownlee M, **Cerami A**. (1985). Recognition and uptake of human diabetic peripheral nerve myelin by macrophages. *Diabetes* 34: 553557.
164. Chang JCF, Ulrich PC, Bucala R, **Cerami A**. (1985). Detection of an advanced glycosylation

product bound to protein *in situ*. J Biol Chem 260: 70707074.

165. Ulrich P, Pongor S, Chang JCF, Bencsath FA, **Cerami A.** (1985). Aging of proteins. The furoyl furanyl imidazole crosslink as a key advanced glycosylation event. In Modification of Proteins During Aging. Adelman RC (ed). New York: Liss. p 8392.

166. Bucala R, Gallati M, Manabe S, Cotlier E, **Cerami A.** (1985). Glucocorticoid lens protein adducts in experimentally induced steroid cataracts. Exp Eye Res 40: 853863.

167. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YCE, Mathison J, Ulevitch R, **Cerami A.** (1985). Identity of tumor necrosis factor and the macrophage secreted factor cachectin. Nature 316: 552554.

168. Bucala R, **Cerami A.** (1985). Nonenzymatic modification of proteins by steroids: pathological implications for autoimmunity and glucocorticoid toxicity. BioEssays 3: 5559.

169. Torti FM, Dieckmann B, Beutler B, **Cerami A,** Ringold GM. (1985). A macrophage factor inhibits adipocyte gene expression: an *in vitro* model of cachexia. Science 229: 867869.

170. Beutler B, Milsark IW, **Cerami A.** (1985). Passive immunization against cachectin/ tumor necrosis factor (TNF) protects mice from the lethal effect of endotoxin. Science 229: 869871.

171. Vlassara H, Brownlee M, **Cerami A.** (1985). Highaffinity receptor mediated uptake and degradation of glucose modified proteins: A potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 82: 55885592.

172. Brownlee M, Vlassara H, **Cerami A.** (1985). Nonenzymatic glycosylation products on collagen covalently trap low density lipoprotein. Diabetes 34: 938941.

173. **Cerami A.** (1985). Accumulation of advanced glycosylation endproducts on proteins and nucleic acids: role in ageing. In Cellular and Molecular Aspects of Aging: The Red Cell as a Model. New York: Liss. p 7988.

174. **Cerami A.** (1985). Hypothesis: Glucose as a mediator of aging. J Am Geriatrics Soc 33: 626634.

175. Bucala R, Manabe S, Urban RC, **Cerami A.** (1985). Nonenzymatic modification of lens crystallins by prednisolone induces sulfhydryl oxidation and aggregate formation: *in vitro* and *in vivo* studies. Exp Eye Res 41: 353363.

176. **Cerami A,** Vlassara H, Brownlee M. (1985). Protein glycosylation and the pathogenesis of

atherosclerosis. *Metabolism* 34: 3744.

177. Dayer JM, Beutler B, **Cerami A.** (1985). Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E₂ production by human synovial cells and dermal fibroblasts. *J Exp Med* 162: 21632168.

178. Beutler B, **Cerami A.** (1985). Recombinant interleukin-1 suppresses lipoprotein lipase activity in 3T3L1 cells. *J Immunol* 135: 39693971.

179. Beutler B, Milsark IW, **Cerami A.** (1985). Cachectin/tumor necrosis factor: Production, distribution and metabolic fate *in vivo*. *J Immunol* 135: 39723977.

180. **Cerami A,** Ikeda Y, Le Trang N, Hotez PJ, Beutler B. (1985). Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). *Immunol Letters* 11: 173177.

181. Bucala R, Model P, Russel M, **Cerami A.** (1985). Modification of DNA by glucose 6-phosphate induces DNA rearrangements in an Escherichia coli plasmid. *Proc Natl Acad Sci USA* 82: 84398442.

182. **Cerami A,** Beutler B. (1985). Role of cachectin in malnutrition. In *Study Week on: Interaction of Parasitic Diseases and Nutrition*. Chagas C, Keusch GT (eds). Vatican: Pontifica Academia Scientiarum.

183. Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer C, **Cerami A.** (1986). Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. *Proc Natl Acad Sci USA* 83:16701674.

184. **Cerami A,** Vlassara H, Brownlee M. (1986). Role of nonenzymatic glycosylation in atherogenesis. In *Perspectives in Inflammation, Neoplasia and Vascular Cell Biology*. Proceedings of The UCLA Symposia on Molecular and Cellular Biology. pp 105114, Edgington T, Ross R, Silverstein S (eds). New York: Liss. *J Cell Biochem* 30:111120.

185. Monnier VM, **Cerami A.** 1986. Nonenzymatic browning of proteins. In *Methods in Diabetes Research, Volume II*. Clarke WL, Larner J, Pohl SL (eds). New York: Wiley. p 533543.

186. Beutler B, Krochin N, Milsark IW, Luedke C, **Cerami A.** (1986). Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance. *Science* 232: 977980.

187. Vlassara H, Brownlee M, **Cerami A.** (1986). Monocyte/macrophage accumulation of human peripheral nerve myelin which is modified by advanced glycosylation: implications for diabetes and aging. In *Proceedings of the Second International Conference on the Use of Human Tissues and Organs for Research and Transplant*. Bridges LM, Cades JS, Luskin HA (eds). Philadelphia: National Diabetes

Research Interchange. p 112118.

188. Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, **Cerami A**, Figari IS, Palladino MA, O'Connor JV. (1986). Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin1. *J Exp Med* 163: 1433-1450.

189. Beutler B, **Cerami A**. (1986). Cachectin and tumour necrosis factor as two sides of the same biological coin. *Nature* 320: 584-588.

190. Henderson GB, Ulrich P, Fairlamb AH, **Cerami A**. (1986). Synthesis of the trypanosomatid metabolites trypanothione, and N1mono and N8monoglutathionyl-spermidine. *J Chem Soc Chem Commun* 593594.

191. Brownlee M, Vlassara H, Kooney A, Ulrich P, **Cerami A**. (1986). Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. *Science* 232: 1629-1632.

192. Jones RL, Grady RW, Sorette MP, **Cerami A**. (1986) Host-associated iron transfer factor in normal humans and patients with transfusion siderosis. *J Lab Clin Med* 107:431-438.

193. Shames SL, Fairlamb AH, **Cerami A**, Walsh CT. (1986). Purification and characterization of trypanothione reductase from *Crithidia fasciculata*, a newly discovered member of the family of disulfide-containing flavoprotein reductases. *Biochem* 25: 3519-3526.

194. **Cerami A**, Crabbe MJC. (1986). Recent advances in ocular cataract research. *Trends Pharma Sci* 7: 271-274.

195. **Cerami A**. (1986). Aging of proteins and nucleic acids: What is the role of glucose? *Trends Biochem Sci* 11: 311-314.

196. Bucala R, Ulrich PC, Chait BT, Bencsath FA, **Cerami A**. (1986). Structure of lysine adducts with 16 α -hydroxyestrone and cortisol. *J Steroid Biochem* 25: 127-133.

197. **Cerami A**, Brownlee M, Vlassara H. (1986). Nonenzymatic glycosylation of proteins and nucleic acids: Role in the complications of diabetes. In *Diabetes (1985), Proceedings of the XII Congress of the International Diabetes Federation*, Serrano-Rios M, Lefebvre PJ (eds). Amsterdam: Elsevier p 613-617.

198. Brownlee M, Vlassara H, **Cerami A**. (1986). Protein trapping and crosslinking by nonenzymatic glycosylation products: Role in diabetic vascular occlusion. In *Diabetes (1985), Proceedings of the XII Congress of the International Diabetes Federation*, Serrano-Rios M, Lefebvre PJ (eds). Amsterdam: Elsevier p 618-622.

199. Brownlee M, Vlassara H, **Cerami A.** (1986). Trapped immunoglobulins on peripheral nerve myelin from patients with diabetes mellitus. *Diabetes* 35: 9991003.
200. Tracey KJ, Lowry SF, Beutler B, **Cerami A,** Albert JD, Shires GT. (1986). Cachectin /tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential. *J Exp Med* 164: 13681373.
201. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ III, Zentella A, Albert JD, Shires GT, **Cerami A.** (1986). Shock and tissue injury induced by recombinant human cachectin. *Science* 234: 470474.
202. Beutler B, Tkacenko V, Milsark I, Krochin N, **Cerami A.** (1986). The effect of t interferon on cachectin expression by mononuclear phagocytes reversal of the lpsd (endotoxin resistance) phenotype. *J Exp Med* 164: 17911796.
203. Vlassara H, Brownlee M, **Cerami A.** (1986). Novel macrophage receptor for glucosemodified proteins is distinct from previously described scavenger receptors. *J Exp Med* 164: 13011309.
204. Vlassara H, Brownlee M, **Cerami A.** (1986). Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications. *Clin Chem* 32: B37B41.
205. Vlassara H, Spiegel RJ, San Doval D, **Cerami A.** (1986). Reduced plasma lipoprotein lipase activity in patients with malignancyassociated weight loss. *Horm Metabol Res* 18: 698703.
206. Vlassara H, Brownlee M, **Cerami A.** (1986). Macrophage receptor for proteins modified by nonenzymatic glycosylation is distinct from previously described scavenger receptors. In *Diabetes (1985), Proceedings of the XII Congress of the International Diabetes Federation*. SerranoRios M, Lefebvre PJ (eds). Amsterdam: Elsevier. p 637641.
207. Fairlamb AH, Henderson GB, **Cerami A.** (1986). The biosynthesis of trypanothione and Nlglutathionylspermidine in *Crithidia fasciculata*. *Mol Biochem Parasitol* 21: 247257.
208. **Cerami A,** Beutler B. (1986). Cachectin: The dark side of tumor necrosis factor. In *Symposia on Quantitative Biology on Molecular Biology of Homo Sapiens, Volume 51*. Cold Spring Harbor. p 625-629.
209. Brownlee M, Vlassara H, Kooney T, **Cerami A.** (1986). Inhibition of glucose-derived protein crosslinking and prevention of early diabetic changes in glomerular membrane by aminoguanidine. *Diabetes* 35 suppl 1.
210. **Cerami A,** Beutler B. (1986). Molecular basis for the cachexia of parasitic diseases. In *Molecular*

Strategies of Parasitic Invasion (UCLA Symposium on Molecular and Cellular Biology, New Series, Volume 42). Agabian N, Goodman H, Noguiera N (eds). New York: Liss. p 3-14.

211. Beutler B, **Cerami A.** (1987). Cachectin: more than a tumor necrosis factor. *N Engl J Med* 316: 379385.

212. Mosser DM, Vlassara H, Edelson PJ, **Cerami A.** (1987). Leishmania promastigotes are recognized by the macrophage receptor for advanced glycosylation endproducts. *J Exp Med* 165: 140145.

213. Bucala R, Lahita RG, Fishman J, **Cerami A.** (1987). Antiestrogen antibodies in users of oral contraceptives and in patients with systemic lupus erythematosus. *J Exp Immunol* 67: 167175.

214. Beutler B, **Cerami A.** (1987). The endogenous mediator of endotoxic shock. *Clin Res* 35: 192197.

215. **Cerami A,** Vlassara H, Brownlee M. (1987). Glucose and aging. *Sci Am* 256(5): 9096.

216. Tracey KJ, Lowry SF, Fong Y, Hesse D, Beutler B, Manogue KR, Calvano S, Wei H, Albert JD, **Cerami A,** Shires GT. (1987). Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. *Surg Gynecol Obstet* 164: 415-422.

217. Henderson GB, Fairlamb AH, Ulrich P, **Cerami A.** (1987). Substrate specificity of the flavoprotein trypanothione disulfide reductase from *Crithidia fasciculata*. *Biochem.* 26: 3023-3027.

218. Henderson GB, Fairlamb AH, **Cerami A.** (1987). Trypanothionedependent peroxide metabolism in *Crithidia fasciculata* and *Trypanosoma brucei*. *Molec Biochem Parasitol* 24: 3945.

219. Fairlamb AF, Henderson GB, Bacchi CJ, **Cerami A.** (1987). *In vivo* effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of *Trypanosoma brucei brucei*. *Molec Biochem Parasitol* 24: 185-191.

220. Vlassara H, Valinsky J, Brownlee M, Cerami C, Nishimoto S, **Cerami A.** (1987). Advanced glycosylation endproducts on erythrocyte cell surface induce receptor-mediated phagocytosis by macrophages: a model for turnover of aging cells. *J Exp Med* 166: 539-549.

221. **Cerami A,** Tracey KJ, Lowry SF, Beutler B. (1987). Cachectin: A pluripotent hormone released during the host response to invasion. *Recent Progress in Hormone Research.* 43: 99-112.

222. Lee AT, **Cerami A.** (1987). The formation of reactive intermediate(s) of glucose 6-phosphate and lysine capable of rapidly reacting with DNA. *Mutation Res* 179: 151-158.

223. Lee MD, Zentella A, Pekala PH, **Cerami A.** (1987). Effect of endotoxin-induced monokines on glucose metabolism in the muscle cell line L6. *Proc Natl Acad Sci USA* 84: 2590-2594.
224. Hotez PJ, Le Trang N, **Cerami A.** (1987). Hookworm antigens: the potential for vaccination. *Parasitol Today*. 3: 247-249.
225. Jennings FW, Ulrich P, **Cerami A.** (1987). Chemotherapy of trypanosomiasis: The use of guanylhydrazone compounds in the treatment of experimental murine trypanosomiasis. *Trop Med Parasitol* 38: 181-186.
226. Sassa S, Wolpe S, **Cerami A.** (1987). Inhibition of erythroid differentiation of mouse erythroleukemia cells by a macrophage product(s). *Blood Cells* 13: 161-169.
227. Wolpe SD, Sassa S, **Cerami A.** (1987). Macrophages secrete an inhibitory factor for mouse erythroleukemic cell differentiation: characterization and partial purification. In *The Inhibitors of Hematopoiesis*. Najman A et.al. (eds). Libbey. p 197-200.
228. Tracey KJ, Lowry SF, **Cerami A.** (1987). Cachectin/TNF: A mediator of lethal endotoxemia. In *Molecular Basis of Lymphokine Action*. Webb DR, Pierce CW, Cohen S (eds). Clifton, NJ, Humana press. p 261-269.
229. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, **Cerami A.** (1987). Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia in baboons. *Nature* 330: 662-664.
230. Lee AT, **Cerami A.** (1987). Elevated glucose 6phosphate levels are associated with plasmid mutations *in vivo*. *Proc Natl Acad Sci USA* 84: 8311-8314.
231. Beutler B, **Cerami A.** (1987). Cachectin: A monokine implicated as a mediator of cachexia and shock. In *Lymphokines, Volume 14*. Pick E (ed). New York: Academic. p 203-222.
232. Brownlee M, Vlassara H, **Cerami A.** (1987). The pathogenetic role of nonenzymatic glycosylation in diabetic complications. In *Diabetic Complications: Scientific and Clinical Aspects*. Crabbe MJC (ed). London: Pitman. p 94-139.
233. Tracey KJ, Lowry SF, **Cerami A.** (1987). Physiological responses to cachectin. In *1987 Tumour Necrosis Factor and Related Cytotoxins*. Wiley, Chichester (Ciba Foundation Symposium 131). p 88-108.
234. **Cerami A.**, Beutler B. (1988). The role of cachectin/TNF in endotoxic shock and cachexia. *Immunol Today* 9:28-31.

235. Tracey KJ, Lowry SF, **Cerami A.** (1988). Cachectin: A hormone that triggers acute shock and chronic cachexia. *J Inf Dis* 157:413-420.
236. Manogue KR, **Cerami A.** (1988). Cachectin (tumor necrosis factor): a macrophage protein that induces a catabolic state and septic shock in infected animals. In *Cellular and Molecular Aspects of Inflammation*. Poste G, Crooke ST (eds). New York: Plenum. p 123-150.
237. Beutler B, **Cerami A.** (1988) An endogenous mediator of cellular catabolism and shock. In *Advances in Inflammation Research*, Volume 12. New York: Raven. p 23-32.
238. Beutler B, **Cerami A.** (1988). Cachectin (tumor necrosis factor): A macrophage hormone governing cellular metabolism and inflammatory response. *Endocrine Rev* 9: 57-66.
239. Tracey KJ, Lowry SF, **Cerami A.** (1988). Cachectin/TNF mediates the pathophysiological effects of bacterial endotoxin/lipopolysaccharide (LPS). (1988). In *Bacterial Endotoxin: Pathophysiological Effects, Clinical Significance, and Pharmacological Control (Progress in Clinical and Biological Research*. Levin J, Büller HR, van Deventer SJH, Sturk A (eds). New York: Liss. 272:77-88.
240. Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA Jr, **Cerami A**, Shires GT, Lowry SF. (1988). Cytokine appearance in human endotoxemia and primate bacteremia. *Surg Gyn Obstet* 166: 147-153.
241. Wolpe SD, Davatelis G, Sherry B, Beutler B, Hesse DG, Nguyen HT, Moldawer LL, Nathan CF, Lowry SF, **Cerami A.** (1988). Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. *J Exp Med* 167: 570-581.
242. Vlassara H, Brownlee M, **Cerami A.** (1988). Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels *in vivo*. *Diabetes* 37: 456-461.
243. Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, Beutler B, Cotran RS, **Cerami A**, Lowry SF. (1988). Cachectin/TNF induces cachexia, anemia, and inflammation. *J Exp Med* 167: 1211-1227.
244. Farmer JG, Ulrich PC, **Cerami A.** (1988). Novel pyrroles from sulfite-inhibited Maillard reactions: Insight into the mechanism of inhibition. *J Org Chem* 53: 2346-2349.
245. Ranges GE, Zlotnik A, Espevik T, Dinarello CA, **Cerami A**, Palladino MA Jr. (1988). Tumor necrosis factor-alpha/cachectin is a growth factor for thymocytes: Synergistic interactions with other cytokines. *J Exp Med* 167: 1472-1478.
246. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, **Cerami A**, Wolff SM,

Wilmore DW. (1988). Detection of circulating tumor necrosis factor after endotoxin administration. *N Engl J Med* 318: 1481-1486.

247. Radoff S, Vlassara H, **Cerami A.** (1988). Characterization of a solubilized cell surface binding protein on macrophages specific for proteins modified non-enzymatically by advanced glycosylated endproducts. *Arch Biochem Biophys* 263: 418-423.

248. Beutler B, **Cerami A.** (1988). Tumor necrosis, cachexia, shock, and inflammation: A common mediator. *Ann Rev Biochem* 57: 505-518.

249. Tracey KJ, Lowry SF, **Cerami A.** (1988). The pathophysiologic role of cachectin/ TNF in septic shock and cachexia. *Annales Institut Pasteur* 139: 311-317.

250. Zechner R, Thomas NC, Sherry B, **Cerami A,** Breslow JL. (1988). Recombinant human cachectin/tumor necrosis factor but not interleukin-1 α downregulates lipoprotein lipase gene transcription in mouse 3T3-L1 adipocytes. *Molec Cell Biol* 8: 2394-2401.

251. Brownlee M, **Cerami A,** Vlassara H. (1988). Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. *N Engl J Med* 318: 1315-1321.

252. Vlassara H, Brownlee M, Manogue K, Pasagian A, Dinarello C, **Cerami A.** (1988). Cachectin/TNF and IL-1 synthesis and secretion are induced by glucose-modified protein binding to high-affinity macrophage receptor. In *Monokines and other Non-Lymphocytic Cytokines*. New York: Liss. p 145-151.

253. Henderson GB, Ulrich P, Fairlamb AH, Rosenberg I, Pereira M, Sela M, **Cerami A.** (1988). "Subversive" substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease. *Proc Natl Acad Sci USA* 85: 5374-5378.

254. Henderson GB, **Cerami A.** (1988). Host-parasite interface: biochemistry and rational drug design. In *Tropical and Geographic Medicine, Second Edition*. Warren KS, Mahmoud AAF (eds), pp.112-117.

255. Davatelis G, Hermsen K, Wolpe SD, Luedke C, Gallegos C, Coit D, Merryweather J, Tekamp-Olson P, **Cerami A.** (1988), Cloning and characterization of a cDNA for murine MIP, a novel monokine with inflammatory and chemokinetic properties. *J Exp Med* 167: 1939-1944.

256. Beutler B, **Cerami A.** (1988). The history, properties, and biological effects of cachectin. *Biochemistry* 27: 7575-7582.

257. Sherry B, Tekamp-Olson P, Gallegos C, Bauer D, Davatelis G, Wolpe SD, Masiarz F, Coit D, **Cerami A.** (1988). Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1b. *J Exp*

Med 168: 2251-2259.

258. Sherry B, **Cerami A.** (1988). Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. *J Cell Biol* 107: 1269-1277.

259. Manogue KR, **Cerami A.** (1988). The pathological role of cachectin (tumor necrosis factor) in septic shock and chronic disease: *In vivo* evidence. In *Tumor Necrosis Factor/ Cachectin and Related Cytokines*. Bonavida, Gifford, Kirchner, Old (eds). Basel: Karger. p 108-113.

260. Brownlee M, **Cerami A,** Vlassara H. (1988). Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. *Diabetes/Metab Rev* 4: 437-451.

261. Tracey KJ, Lowry SF, **Cerami A.** (1988). Cachectin/TNF- α in septic shock and septic adult respiratory distress syndrome. *Am Rev Resp Dis* 138: 1377-1379.

262. Michie HR, Eberlein TJ, Spriggs DR, Manogue KR, **Cerami A,** Wilmore DW. (1988). Interleukin-2 initiates metabolic responses associated with critical illness in humans. *Ann Surg* 208: 493-503.

263. **Cerami A,** Vlassara H, Brownlee M. (1988). The role of advanced glycosylation products in complications of diabetes. *Diabetes Care* 11: 73-79.

264. Michie HR, Spriggs DR, Manogue KR, Sherman ML, Revhaug A, O'Dwyer ST, Arthur K, Dinarello CA, **Cerami A,** Wolff SM, Kufe DW, Wilmore DW. (1988) Tumor necrosis factor and endotoxin induce similar metabolic responses in humans. *Surgery* 104:280-286.

265. Marano MA, Moldawer LL, Fong Y, Wei H, Minei J, Yurt R, **Cerami A,** Lowry SF. (1988) Cachectin/tumor necrosis factor production in experimental burns and pseudomonas infection. *Arch Surg* 123:1383-1388.

266. Wolpe S, Sherry B, Juers D, Davatelis G, Yurt RW, **Cerami A.** Identification and characterization of macrophage inflammatory protein 2. (1989). *Proc Natl Acad Sci USA* 86: 612-616.

267. Davatelis G, Wolpe SD, Sherry B, Dayer J-M, Chicheportiche R, **Cerami A.** (1989). Macrophage inflammatory protein-1: A prostaglandin-independent endogenous pyrogen. *Science* 243: 1066-1068.

268. Silen ML, Hesse DG, Felsen D, Moldawer LL, Calvano SE, **Cerami A,** Lowry SF. (1989). Cachectin/tumor necrosis factor production by fetal and newborn rat hepatic macrophages. *J Ped Surg* 24: 34-38.

269. **Cerami A,** Brownlee M, Vlassara H. (1989) Treatment of diabetic complications: Prevention of

advanced nonenzymatic glycosylation of proteins. Diabetes 88, Larkins, R., Zimmet, P. (eds.) Elsevier, Amsterdam pp. 421-425.

270. Lee AT, **Cerami A.** (1988) DNA Damage mediated by reducing sugars *in vitro* and *in vivo*. In DNA Replication and Mutagenesis, pp.423-427, Moses R.E., Summers C.(eds), Am Soc for Microbiology, Washington, DC.

271. Fairlamb AH, Henderson GB, **Cerami A.** (1989) Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proc Natl Acad Sci USA 86:2607-2611.

272. Tracey KJ, **Cerami A.** (1988) Cachectin/TNF and other cytokines in infectious disease. Curr Opin Immunol 1:454-461. IM Roitt ed.

273. Tracey KJ, Vlassara H, **Cerami A.** (1989) Cachectin/TNF (tumour necrosis factor). Lancet, Dr. Evans asst ed. London. May 20:1122-1125.

274. Fong Y, Tracey KJ, Lowry SF, **Cerami A.** (1989) Biology of cachectin. In Cytokines. Vol 1:Macrophage-Derived Cell Regulatory Factors. pp 74-88, Sorg, C.(ed) Basel, Karger.

275. Beutler B, **Cerami A.** (1989) The biology of cachectin/TNF - A primary mediator of the host response Ann Rev Immunol 7:625-655.

276. Sherry BA, Gehn J, Fong Y, Marano M, Wei H, **Cerami A,** Lowry SF, Lundholm KG, Moldawer LL. (1989) Anticachectin/tumor necrosis factor-alpha antibodies attenuate the development of cachexia in two murine transplantable tumor models. FASEB J 3:1956-1962.

277. Moldawer LL, Marano M, Wei H, Fong Y, Silen ML, Kuo G, Manogue KR, Vlassara H, Cohen H, **Cerami A,** Lowry SF. (1989) Cachectin/tumor necrosis factor-alpha alters red blood cells kinetics and induces anemia *in vivo*. FASEB J 3:1637-1642.

278. Vlassara H, Brownlee M, **Cerami A.** (1989) Macrophage receptor-mediated processing and regulation of advanced glycosylation endproduct (AGE)-modified proteins: role in diabetes and aging. In The Maillard Reaction in Aging, Diabetes and Nutrition. Baynes JW (ed). New York: Liss. pp. 205-218.

279. Lee AT, **Cerami A.** (1989) Nonenzymatic glycosylation of DNA by reducing sugars. In The Maillard Reaction in Aging, Diabetes and Nutrition. Baynes, J.W., (ed) New York: Liss. pp. 291-299.

280. Fong Y, Moldawer LL, Marano M, Wei H, Barber A, Manogue K, Tracey KJ, Kuo G, Fischman DA, **Cerami A,** Lowry SF (1989) Cachectin/TNF or IL-1a induces cachexia with redistribution of body proteins. J Am Phys Soc 256:R659-R665, (1989).

281. Romero R, Manogue KR, Mitchell MD, Wu YK, Oyarzun E, Hobbins JC, **Cerami A.** (1989) Cachectin-tumor factor in the amniotic fluid of women with intraamniotic infection and preterm labor. *Amer J Obstet Gynecol* 161:336-341.
282. Tracey KJ, **Cerami A.** (1989) The role of cachectin/tumor necrosis factor in AIDS. *Cancer Cells* 1:62-63.
283. Lee AT, **Cerami A.** (1989) Modifications of proteins and nucleic acids by reducing sugars: Possible role in aging. In *Handbook of the Biology of Aging* 3rd ed., Schneider, E.L. and Baynes, J.W. (eds), pp116-130.
284. Vlassara H, Brownlee M, **Cerami A.** (1989) Advanced non-enzymatic tissue glycosylation: Significance in late diabetic complications. *Diabetes Research and Clinical Practice*, Elsevier, 7:S103-S108.
285. Beutler B, **Cerami A.** (1990) Cachectin (tumor necrosis factor): An endogenous mediator of shock and inflammatory response. In *Immunophysiology: The Role of Cells and Cytokines in Immunity and Inflammation*. Oppenheim, J.J. and Shevach, E.M.(eds.), Oxford University Press, New York, Chp 12:226-237.
286. Broxmeyer HE, Sherry B, Lu L, Cooper S, Carow C, Wolpe SD, **Cerami A.** (1989) Myelopoietic enhancing effects of murine macrophage inflammatory proteins 1 and 2 on colony formation *in vitro* by murine and human bone marrow granulocyte/macrophage progenitor cells. *J Exp Med* 170:1583-93.
287. Wolpe SD, **Cerami A.** (1989) Macrophage inflammatory proteins 1 and 2: Members of a novel superfamily of cytokines. (review) *FASEB J* 3:2565-2573.
288. Titus RG, Sherry B, **Cerami A.** (1989) Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. *J Exp Med* 170:2097-2104.
289. Tracey KJ, **Cerami A.** (1989) Studies of cachexia in parasitic infection. In *Biochemical Science in the Third World: Under the Volcano Annals of the NY Academy of Sciences*, Vol. 569, Bloom, B., Cerami, A., (Eds), pp. 211-218.
290. Murgolo NJ, **Cerami A.**, Henderson GB. (1989) Trypanothione reductase. In *Biochemical Science in the Third World: Under the Volcano Annals of the NY Academy of Sciences*, Vol. 569, Bloom, B., and Cerami, A., (Eds), pp. 193-200.
291. Kwiatkowski D, Cannon JG, Manogue KR, **Cerami A.**, Dinarello C, Greenwook BM. (1989) Tumor necrosis factor production in falciparum malaria and its association with schizont rupture. *Clin. Exp. Immunol.* 77:361-366.

292. Tracey KJ, **Cerami A.** (1990) The biology of cachectin/TNF. In Growth Factors, Differentiation Factors, and Cytokines, Habernicht, A. (ed.) Springer-Verlag, Berlin, pp. 356-365.
293. Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KR, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowery SF, **Cerami A.** (1989) Antibodies to cachectin/TNF reduce interleukin-1b and interleukin-6 appearance during lethal bacteremia. *J Exp Med* 170:1627-1633.
294. Tracey, KJ, **Cerami A.** (1990) Review: Cachectin/TNF in the cachexia of infection In Parasites:Molecular Biology, Drug and Vaccine Design. Agabian, N., and Cerami, A. (eds) Alan R. Liss, NY. pp. 401-410.
295. Murgolo NJ, **Cerami A,** Henderson GB. (1990) Trypanothione In Parasites: Molecular Biology, Drug and Vaccine Design. Agabian N, and **Cerami A.** (eds) Alan R. Liss, NY. pp. 263-277.
296. Goldberg DE, Slater AFG, **Cerami A,** Henderson GB. (1990) Hemoglobin degradation in the malaria parasite Plasmodium falciparum: An ordered process in a unique organelle. *Proc. Natl. Acad. Sci.* 87:2931-2935.
297. Kinkhabwala M, Sehafpal P, Skolnik E, Smith D, Sharma VK, Stenzel KH, Vlassara H, **Cerami A,** Suthanthiran M. (1990) A novel addition to the T cell repertory: Cell-surface expression of tumor necrosis factor/cachectin by activated normal human T cells. *J. Exp. Med.* 171:941-946.
298. Henderson GB, Yamaguchi M, Novoa L, Fairlamb AH, **Cerami A.** (1990) Biosynthesis of the trypanosomatid metabolite trypanothione: Purification and characterization of trypanothione synthetase from *Crithidia fasciculata*. *Biochemistry* 29:3924-3929
299. Henderson GB, Glushka J, Cowburn D, **Cerami A.** (1990) Synthesis and NMR characterization of the trypanosomatid metabolite, N1, N8-Bis(glutathionyl) spermidine disulphide (trypanothione disulphide). *J Chem Soc Perkin Trans.* 1:911-914.
300. Fahey TJ III, Sherry B, Tracey KJ, van Deventer S, Jones WG II, Minei JP, Morgello S, Shires GT, **Cerami A.** (1990) Cytokine production in a model of wound healing: The appearance of MIP-1, MIP-2, cachectin/TNF and IL-1. *Cytokine* 2:92-99.
301. Saukkonen K, Sande S, Cioffe C, Wolpe S, Sherry B, **Cerami A,** Tuomanen E. (1990) The role of cytokines in the generation of inflammation and tissue damage in experimental gram positive meningitis. *J Exp Med* 171:439-448.
302. Lee AT, **Cerami A.** (1990) *In vitro* and *in vivo* reactions of nucleic acids with reducing sugars. *Mutation Res* 238:185-191.

303. Lee AT, **Cerami A.** Nonenzymatic reaction of reducing sugars with DNA (1990) In The Maillard Reaction in Food Processing, Human Nutrition and Physiology. Birkhauser Congress Reports Finot, P.A. (ed), pp.415-423.
304. Tracey KJ, **Cerami A.** (1990) Metabolic responses to cachectin/TNF: A brief review. In Micronutrients and Immune Functions, Annals of The New York Academy of Sciences, 587:325-331.
305. Krungkrai J, **Cerami A,** Henderson GB. (1990) Pyrimidine biosynthesis in parasitic protozoa: Purification of a monofunctional dihydroorotase from *Plasmodium berghei* and *Crithidia fasciculata*. Biochemistry 29:6270-6275.
306. Fong Y, Marano MA, Moldawer LL, Wei H, Calvano SE, Kennedy JS, Allison AC, **Cerami A,** Shires GT, Lowry SF. (1990) The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 85:1896-1904.
307. Minano FJ, Sancibrian M, Vizcaino M, Paez X, Davatelis G, Fahey T, Sherry B, **Cerami A,** Myers RD. (1990) Macrophage inflammatory protein-1: Unique action on hypothalamus to evoke fever. Brain Res Bull, 24:849-852.
308. Moldawer LL, Sherry B, Lowry SF, **Cerami A.** (1989) Endogenous cachectin/tumor necrosis factor-alpha production contributes to experimental cancer-associated cachexia. Cancer Surveys, 8:853-859.
309. Broxmeyer HE, Sherry B, Lu L, Cooper S, Oh K-O, Olson PT, Kwon BS, **Cerami A.** (1990) Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation *in vitro* by bone marrow myeloid progenitor cells. Blood 76:1110-1116.
310. Tracey KJ, **Cerami A.** (1990) The biochemical basis of cachexia of infection. In Immune Recognition and Evasion: Molecular Aspects of Host-Parasite Interaction Van der Ploeg, Vogel (eds), Academic Press, Inc., pp. 163-171.
311. Bucala R, Vlassara H, **Cerami A.** (1990) Fortgeschrittene Glykierung und die Pathogenese der diabetischen Gefässkomplikationen. (Advanced glycosylation and the pathogenesis of diabetic vascular complications.) In Vaskuläre Komplikationen und Therapeutische Konsequenzen beim Diabetes Mellitus, Dreyer M, Dammann H-G. (eds), Springer-Verlag, pp.1-14.
312. Jue D-M, Sherry B, Leudke C, Manogue K, **Cerami A.** (1990) Processing of newly synthesized cachectin/tumor necrosis factor in endotoxin-stimulated macrophages. Biochemistry 29:8371-8377.
313. Olson P-T, Gallegos C, Bauer D, McClain J, Sherry B, Fabre M, van Deventer S, **Cerami A.** (1990) Cloning and characterization of cDNAs for murine macrophage inflammatory protein-2 and its human homologs. J Exp Med 172:911-919.

314. Luedke CE, **Cerami A.** (1990) Interferon-gamma overcomes glucocorticoid suppression of cachectin/tumor necrosis factor biosynthesis. *J Clin Invest* 86:1234-1240.
315. **Cerami A**, Tracey KJ, Sherry B, Manogue K. (1990) TNF- α , MIP-1 and MIP-2 as mediators of the inflammatory process. *Cytokines: Basic Principles and Clinical Applications*, S. Romagnani, A.K. Abbas (eds), Serono symposia publications from Raven Press NY, vol. 68, pp. 13-22.
316. Kwiatkowski D, Hill AVS, Sambou I, Twumasi P, Castracane J, Manogue KR, **Cerami A**, Brewster DR, Greenwood BM. (1990) Tumor necrosis factor concentration in fatal cerebral, non-fatal cerebral, and uncomplicated *Plasmodium falciparum* malaria. *Lancet* 336:1201-1204.
317. Radoff S, **Cerami A**, Vlassara H. (1990) Isolation of a surface binding protein specific for advanced glycosylation endproducts from the murine macrophage-derived cell line RAW 264.7. *Diabetes* 39:1510-1518.
318. Marano M, Fong Y, Moldawer LL, He W, Tracey KJ, Barie PS, Manogue K, Shires GT, **Cerami A**, Lowry S. (1990) Serum cachectin/TNF in critically ill burn patients correlates with infection and mortality. *Surg Gynecol and Obstet* 170:32-38.
319. Kuriyan J, Wong L, Guenther BD, Murgolo NJ, **Cerami A**, Henderson GB. (1990) Preliminary crystallographic analysis of trypanothione reductase from *Crithidia fasciculata*. *J. Mol. Biol.* 215:335-337.
320. Beutler B, **Cerami A.** (1990) Cachectin (tumor necrosis factor) and lymphotoxin as primary mediators of tissue catabolism, inflammation, and shock. In *Lymphokines and the Immune Response* Cohen, S. (ed.) CRC Press, Florida, pp.200-207.
321. Tracey KJ, Morgello S, Koplín B, Fahey TJ, Fox J, Aledo A, Manogue KR, **Cerami A.** (1990) Metabolic effects of cachectin/tumor necrosis factor are modified by site of production: Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominately acute anorexia. *J Clin Invest* 86:2014-2024.
322. Sherry B, Jue D-M, Zentella A, **Cerami A.** (1990) Characterization of high molecular weight glycosylated forms of murine cachectin/TNF. *BBRC* 173:1072-1078.
323. van Deventer SJH, Tracey KJ, Manogue KR, **Cerami A.** (1990) Anti-cachectin/TNF strategies in the treatment of gram-negative septicemia. *Endotoxin: From Pathophysiology to Therapeutic Approaches*, Baumgartner J-D, Calandra T, Carlet J. (eds), Flammarion Medecine-Sciences, Paris, France, pp. 103-111.
324. Bucala R, Ritchlin C, Winchester R, **Cerami A.** (1991) Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. *J Exp Med* 173: (1991).

325. Bucala R, Tracey KJ, **Cerami A.** (1991) Advanced glycosylation products quench nitric oxide and mediate defective endothelium dependent vasodilatation. *J Clin Invest* 87:432-438.
326. Slater AFG, Swiggard WJ, Orton BR, Flitter WD, Goldberg DE, **Cerami A,** Henderson, GB (1991) An iron-carboxylate bond links the heme units of malaria pigment. *Proc Natl Acad Sci USA* 88:325-329.
327. **Cerami A,** Bucala R, Vlassara H. (1991) Advanced Glycation: A common pathogenic mechanism for diabetic complications. In *Diabetic Complications: Epidemiology and Pathogenetic Mechanisms.* Andreani D, Gueriguian JL, and Striker GE, (eds), Serono Symposia Publications, Raven Press vol. 69, pp. 37-44.
328. Krungkrai J, **Cerami A,** Henderson GB. (1991) Purification and characterization of dihydroorotate dehydrogenase from the rodent malaria parasite *Plasmodium berghei*. *Biochemistry,* 30:1934-1939.
329. Sherry B, **Cerami A.** (1991) Small cytokine superfamily. *Curr. Opinion in Imm.* 3:56-60.
330. Minano FJ, Sancibrian M, Vizcaino M, Paez X, Davatelis G, Fahey T, **Cerami A,** Myers RD (1990) Pharmacological characterization of fever evoked by intrahypothalamic macrophage inflammatory protein-1. *Europ J Pharmacol* 183:883.
331. Titus RG, Sherry B, **Cerami A.** (1991) The involvement of TNF, IL-1 and IL6 in the immune response to protozoan parasites. *Immunoparasitology Today* 12(3):A13-A16.
332. Goldberg DE, Slater AS, Beavis R, Chait B, **Cerami A,** Henderson GB (1991) Hemoglobin degradation in the human malaria pathogen *Plasmodium falciparum*: A catabolic pathway initiated by a specific aspartic protease. *J Exp Med* 173:961-969.
333. Widmer U, Yang Z, van Deventer S, Manogue K, Sherry B, **Cerami A.** (1991) Genomic structure of murine macrophage inflammatory protein (MIP)-1a: Conservation of potential regulatory sequences with the human homolog LD78. *J Immunol* 146:4031-4040.
334. Lee AT, **Cerami A.** (1991) Induction of gamma-delta transposition in response to elevated glucose-6-phosphate levels. *Mutation Research* 249:125-133.
335. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Friedman EA, **Cerami A,** Vlassara, H. (1991) Advanced glycosylation endproducts in patients with diabetic nephropathy. *N Engl J Med* 325:836-842.
336. Yang Z, Makita Z, Horii Y, Brunelle S, **Cerami A,** Sehajpal P, Suthanthiran M, Vlassara H. (1991) Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: Relationship to macrophage receptor for glucose-modified proteins. *J Exp Med* 174:515-524.

337. Manogue K, van Deventer S, **Cerami A.** (1991) Tumor Necrosis Factor-Alpha or Cachectin. Immunology and Molecular Biology of Cytokines: The Cytokine Handbook Thomson, A.W. (ed), Academic Press Ltd. U.K. pp. 241-256.
338. Tracey KJ, **Cerami A.** (1991) Pleiotropic effects of TNF in infection and neoplasia: Beneficial, inflammatory, catabolic, or injurious. In Tumor Necrosis Factors: Structure Function and Mechanism of Action, Agarwhal BB, and Vilcek JT (eds), pp. 431-452.
339. Kuriyan J, Kong X-P, Krishna TSR, Sweet RM, Murgolo NJ, Field H, **Cerami A**, Henderson GB (1991) X-ray structure of trypanothione reductase from *Crithidia fasciculata* at 2.4 Å resolution. Proc Natl Acad Sci, USA 88:8764-8768.
340. Henderson GB, Murgolo NJ, Kuriyan J, Osapay K, Kominos D, Berry A, Scrutton NS, Hinchliffe NW, Perham RN, **Cerami A.** (1991) Engineering the substrate specificity of glutathione reductase towards trypanothione reduction. Proc Natl Acad Sci, USA 88:8769-8773.
341. Broxmeyer HE, Sherry B, Cooper S, Ruscetti FW, Williams DE, Arosio P, Kwon BS, **Cerami A.** (1991) Macrophage inflammatory protein (MIP) - 1b abrogates the capacity of MIP-1a to suppress myeloid progenitor cell growth. J Immunol 147:2586-2594.
342. Li B, Sehajpal PK, Khanna A, Vlassara H, **Cerami A**, Stenzel KH, Suthanthiran M. (1991) Differential regulation of transforming growth factor beta and interleukin-2 genes in human T-cells: Demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction. J Exp Med 174:1259-1262.
343. Tracey KJ, **Cerami A.** (1991) Cachectin-TNF in the biology of disease. In Molecular Mechanisms and Their Clinical Application in Malignancies vol. 12, Bristol-Myers Squibb Cancer Symposia, Bergsagel D, Mak TW (eds), Academic Press Inc., San Diego, CA. pp.125-133.
344. Yamin MA, Brownlee M, **Cerami A**, Vlassara H. (1991) Nonenzymatic glycosylation of matrix and the pathogenesis of diabetic angiopathy. J Nephrol 1:23-26.
345. Slater AFG, **Cerami A.** (1992) Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature 355:167-169.
346. Bucala R, Vlassara H, **Cerami A.** (1992) Advanced glycosylation endproducts. In Post-Translational Modifications of Proteins, Harding JJ, James M, Crabbe C, (eds), CRC Press Inc. Boca Raton, FL.
347. Sherry B, Horii Y, Manogue KR, Widmer U, **Cerami A.** (1992) Macrophage inflammatory proteins 1 and 2: An overview. In Interleukin 8 (NAP-1) and Related Chemotactic Cytokines Baggiolini, M., Sorg, C., (eds), S. Karger, Basel Switzerland, vol. 4, pp. 117-130.

348. **Cerami A.** (1992) Inflammatory cytokines. *Clin Immunol Immunopathol* 62:S3-S10.
349. Field H, **Cerami A**, Henderson GB. (1992) Cloning, sequencing, and demonstration of polymorphism in trypanothione reductase from *Crithidia fasciculata*. *Molec. Biochem. Parasitol.* 50:47-56.
350. Bucala R, **Cerami A.** (1992) Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging. In *Advances in Pharmacology* Vol. 23, Academic Press Inc. pp. 1-34.
351. Schluger N, Sepkowitz K, Armstrong D, Bernard E, Rifkin M, **Cerami A**, Bucala R. (1991) Detection of *Pneumocystis carinii* in serum of AIDS patients with pneumocystis pneumonia by the polymerase chain reaction. *J Protozool* 38:S240-S242.
352. Fahey T.J. III, Tracey KJ, **Cerami A.** (1992) Tumor necrosis factor (cachectin) and the adult respiratory distress syndrome. In *Update: Pulmonary Diseases and Disorders* Fishman, A.P. (ed) McGraw Hill Inc., pp. 175-183.
353. Makita Z, Vlassara H, **Cerami A**, Bucala R. (1992) Immunochemical detection of advanced glycosylation endproducts *in vivo*. *J Biol Chem* 267:5133-5138.
354. Sherry B, Yarlett N, Strupp A, **Cerami A.** (1992) Identification of cyclophilin as a pro-inflammatory secretory product of LPS-activated macrophages. *Proc Natl Acad Sci USA* 89:3511-3515.
355. Fahey TJ III, Tracey KJ, Tekamp-Olson P, Cousens LS, Jones WG, Shires GT, **Cerami A**, Sherry B. (1992) Macrophage inflammatory protein 1 modulates macrophage function. *J Imm* 148:2764-2769.
356. Fairlamb AH, **Cerami A.** (1992) Metabolism and functions of trypanothione in the Kinetoplastida. *Annu Rev Microbiol* 46:695-729.
357. Lolis E, Sweet RM, Cousens LS, Tekamp-Olson P, Sherry BA, **Cerami A.** (1992) Preliminary crystallographic analysis of murine macrophage inflammatory protein 2. *J Mol Biol* 225:913-915.
358. Tracey KJ, **Cerami A.** (1992) Tumor necrosis factor in the malnutrition (cachexia) of infection and cancer. *Am J Trop Hyg* 47(a) suppl., pp.2-7.
359. Radema SA, van Deventer SJ, **Cerami A.** (1991) Interleukin 1 is expressed predominantly by enterocytes in experimental colitis. *Gastroenterology* 100:1180-6.
360. Tracey KJ, **Cerami A.** (1992) TNF and regulation of metabolism in infection: Role of systemic vs. tissue levels. *PSEBM* 200:233-239.

361. Hogan M, **Cerami A**, Bucala R. (1992) Advanced glycosylation endproducts block the anti-proliferative effect of nitric oxide: Role in the vascular and renal complications of diabetes mellitus. *J Clin Invest* 90:1110-1115.
362. Tracey KJ, **Cerami A**. (1992) Tumor necrosis factor α . *Encycl Imm. Roitt, I.M., Delves, P.J. (eds). Saunders Scientific Publications.*
363. Tracey KJ, **Cerami A**. (1992) Tumor necrosis factor in metabolism of disease: Hormonal actions versus local tissue effects. *Hematologie* 34 [Suppl]:S37-S42.
364. Maze R, Sherry B, Kwon BS, **Cerami A**, Broxmeyer HE. (1992) Myelosuppressive effects *in vivo* of purified recombinant murine macrophage inflammatory protein-1 α . *J Immunol* 149:1004-1009.
365. Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, **Cerami A**, Bucala R. (1992) Hemoglobin-AGE: A circulating marker of advanced glycosylation. *Science* 258:651-653.
366. Schluger N, Godwin T, Sepkowitz K, Armstrong D, Bernard E, Rifkin M, **Cerami A**, Bucala R. (1992) Application of DNA amplification to pneumocystosis: Presence of serum *Pneumocystis carinii* DNA during human and experimentally-induced *Pneumocystis carinii* pneumonia. *JEM* 176:1327-1333.
367. Awad S, Henderson GB, **Cerami A**, Held KD. (1992) Effects of trypanothione on the biological activity of irradiated transforming DNA. *IJRB* 62:401-407.
368. Vlassara H, Fuh H, Makita Z, Krungkrai S, **Cerami A**, Bucala R. (1992) Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals: A novel model for diabetic and aging complications. *Proc Natl Acad Sci, USA* 89:12043-12047.
369. Gronowicz G, Hadjimichael J, Richards D, **Cerami A**, Rossomando E.F. (1992) Correlation between tumor necrosis factor- α (TNF- α)-induced cytoskeletal changes and human collagenase gene induction. *J Periodontal Research* 27:562-568.
370. Lee AT, **Cerami A**. (1992) Role of glycation in aging. *Aging and Cellular Defense Mechanisms Vol 663:63-70*, C Francheschi, G Crepaldi, VJ Cristofalo, J Vijg (eds). *Annals of the New York Academy of Sciences. The New York Academy of Sciences, NY, NY.*
371. Bucala R, Lee AT, Rourke L, **Cerami A**. (1993) Transposition of an *Alu*-containing element induced by DNA-advanced glycosylation endproducts. *Proc Natl Acad Sci USA* 90:2666-2670.
372. Broxmeyer HE, Sherry B, Cooper S, Lu L, Maze R, Beckmann MP, **Cerami A**, Ralph P. (1993) Comparative Analysis of the Human Macrophage Inflammatory Protein Family of Cytokines (Chemokines) on Proliferation of Human Myeloid Progenitor Cells. *J Immunol* 150:3448-3458.

373. Widmer U, Manogue KR, **Cerami A**, Sherry B. (1993) Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1a and MIP-1b, members of the chemokine superfamily of proinflammatory cytokines. *J Immunol* 150:4996-5012.
374. Tracey KJ, **Cerami A**. (1993) Tumor necrosis factor (cachectin) in septic/endotoxic shock. *Handbook of Mediators in Septic Shock* Chp.14:291-308. Neugebauer, EA and Holaday, JW (eds). CRC Press, Inc.
375. Sherry B, **Cerami A**. (1993) Macrophage inflammatory protein-1. In *Cytokines of the Lung* 61:369-380. Kelley, J (ed). Marcel Dekker, Inc., NY, NY.
376. Sepkowitz K, Schluger N, Godwin T, Armstrong D, **Cerami A**, Bucala R. (1993) DNA amplification in experimental pneumocystosis: Characterization of serum *Pneumocystis carinii* DNA and potential *P. carinii* carrier states. *J Infectious Diseases* 168:421-426.
377. Myers RD, Paez X, Roscoe AK, Sherry B, **Cerami A**. (1993) Fever and feeding: Differential actions of macrophage inflammatory protein-1 (MIP-1), MIP-1a and MIP 1b on rat hypothalamus. *Neurochemical Research* 18:667-673.
378. Bucala R, Makita Z, Koschinsky T, **Cerami A**, Vlassara H. (1993) Lipid advanced glycosylation: Pathway for lipid oxidation *in vivo*. *Proc Natl Acad Sci USA* 90:6434-6438.
379. Chen H-JC, **Cerami A**. (1993) Mechanism of inhibition of advanced glycosylation by aminoguanidine *in vitro*. *J Carbohydrate Chemistry* 12:731-742.
380. **Cerami A**. (1993) Tumor necrosis factor as a mediator of shock, cachexia and inflammation. *J Blood Purification* 11:108-117.
381. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, **Cerami A**, Bucala R. (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. *Nature* 365:756-759.
382. Tracey KJ, **Cerami A**. (1993) Tumor necrosis factor: An updated review of its biology. *Critical Care Med* 21:S415-S422.
383. Tracey KJ, **Cerami A**. Tumor necrosis factor, other cytokines and disease. (1993) *Ann Rev Cell Biol* 9:317-343.
384. Zentella A, Manogue KR, **Cerami A**. (1993) Cachectin/TNF mediated lactate production in cultured myocytes is linked to activation of futile substrate cycle. *Cytokine* 5(5):436-447.

385. Bucala R, Vlassara H, **Cerami A.** (1994) Measurement of advanced glycosylation endproducts. Diabetes Forum Series Vol V. Research Methodologies in Human Diabetes-Part 1:273-286. Walter de Gruyter, Berlin-New York.
386. Hogan M, Sherry B, Ritchlin C, Fabre M, Winchester R, **Cerami A,** Bucala R. (1994) Differential expression of the small inducible cytokines GRO α and GRO β by synovial fibroblasts in chronic arthritis: Possible role in growth regulation. Cytokine 6(1):61-69.
387. Tracey KJ, **Cerami A.** (1994) TNF: A pleiotropic cytokine and therapeutic target. Ann Rev Med 45:491- 503.
388. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR, **Cerami A,** Vlassara H. (1994) Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343:1519-1522.
389. Bucala R, Vlassara H, **Cerami A.** (1994) Advanced glycosylation endproducts: Role in diabetic and non-diabetic vascular disease. Drug Development Research 32:77-89.
390. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, **Cerami A.** (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer's Disease. Proc Natl Acad Sci USA 91:4766-4770.
391. Lee AT, DeSimone C, **Cerami A,** Bucala R. (1994) Comparative analysis of DNA mutations in *lacI* transgenic mice with age. FASEB Journal 8:545-550.
392. Bernhagen J, Calandra T, **Cerami A,** Bucala R. (1994) Macrophage migration inhibitory factor is a neuroendocrine mediator of endotoxaemia. Trends in Microbiology 2:198-201.
393. **Cerami A,** Warren KS. (1994) Drugs. Parasitology Today 10(10):404-406.
394. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, **Cerami A,** Vlassara H. (1994) Modification of low density lipoprotein by advanced glycation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441-9445.
395. Bucala R, Spiegel LA, Chesney J, Hogan M, **Cerami A.** (1994) Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Molecular Medicine 1:71-81.
396. Bernhagen J, Mitchell RA, Calandra T, Voelter W, **Cerami A,** Bucala R. (1994) Purification, bioactivity and secondary structure analysis of murine and human macrophage inhibitory factor (MIF). Biochemistry 33:14144-14155.

397. Bernhagen J, Calandra T, Mitchell RA, Voelter W, **Cerami A**, Bucala R. (1994) Macrophage migration inhibitory factor is a cytokine secreted by the pituitary after endotoxin stimulation. Cytokines in Hemopoiesis, Oncology and Immunology III Freund/Link/Schmidt/Welte (eds). Springer-Verlag, Berlin Heidelberg.

398. **Cerami A**. The role of the maillard reaction *in vivo*. (1994) Proceedings of the 5th Int'l Symposium on the Maillard Reaction-Maillard Reactions in Chemistry, Food, and Health 151:1-10. T.Labuza, G.Reineccius, V.Monnier, J.O=Brien and J.Baynes (eds). The Royal Society of Chemistry, Cambridge, UK.

399. Lee A, **Cerami A**, Bucala R. (1994) Glucose-mediated DNA damage and mutations: *In vitro* and *in vivo*. Proceedings of the 5th Int'l Symposium on the Maillard Reaction-Maillard Reactions in Chemistry, Food, and Health 151:249-253. T.Labuza, G.Reineccius, V.Monnier, J.O=Brien and J.Baynes (eds). The Royal Society of Chemistry, Cambridge, UK.

400. Bucala R, Makita Z, Koschinsky T, **Cerami A**, Vlassara H. (1994) Advanced glycosylation of LDL: Role in oxidative modification and diabetic complications. Proceedings of the 5th Int'l Symposium on the Maillard Reaction-Maillard Reactions in Chemistry, Food, and Health 151:286-291. T.Labuza, G.Reineccius, V.Monnier, J.O=Brien and J.Baynes (eds). The Royal Society of Chemistry, Cambridge, UK.

401. Lee AT, Plump A, DeSimone C, **Cerami A**, Bucala R. (1995) A role for DNA mutations in Diabetes-associated teratogenesis in transgenic embryos. *Diabetes* 44:20-24.

402. Dubrovsky L, Ulrich P, Nuovo GJ, Manogue KR, **Cerami A**, Bukrinsky M. (1995) Nuclear localization signal of HIV-1 as a novel target for therapeutic intervention. *Molecular Medicine* 1(2):217-230.

403. Bianchi M, Ulrich P, Bloom O, Meistrell III M, Zimmerman GA, Schmidtmayerova H, Bukrinsky M, Donnelly T, Bucala R, Sherry B, Manogue KR, Tortolani AJ, **Cerami A**, Tracey KJ. (1995) An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. *Molecular Medicine* 1(3):254-266.

404. Palinski W, Koschinsky T, Butler SW, Miller E, Vlassara H, **Cerami A**, Witztum JL. (1995) Immunological evidence for the presence of advanced glycosylation endproducts in atherosclerotic lesions of euglycemic rabbits. *Arterioscler Thromb Vasc Biol* 15(5):571-582.

405. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, **Cerami A**. (1995) Identification of the major site of apolipoprotein-B modification by advanced glycosylation endproducts blocking uptake by the low density lipoprotein receptor. *Biological Chemistry* 270:10828-10832.

406. Zimmerman GA, Meistrell III M, Bloom O, Cockcroft KM, Bianchi M, Risucci D, Broome J, Farmer P, **Cerami A**, Vlassara H, Tracey K. (1995) Neurotoxicity of advanced glycation endproducts (AGEs)

during focal stroke, and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci USA 92:3744-3748.

407. Bucala R, **Cerami A**, Vlassara H. (1995) Advanced glycosylation endproducts in diabetic complications: Biochemical basis and prospects for therapeutic intervention. Diabetes Reviews 3(2):258-268.

408. Bucala R, **Cerami A**. (1995) Glucose as a risk factor for atherosclerosis. Proceedings of the 3rd Int'l Symposium on Multiple Risk Factors in Cardiovascular Disease. A.M. Gotto et al. (eds). Kluwer Academic Publishers and Fondazione Giovanni Lorenzini, Netherlands.

409. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, **Cerami A**, Bucala R. (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377:68-71.

410. Sherry BA, Alava G, Tracey KJ, Martiney J, **Cerami A**, Slater AFG. (1995) Malaria-specific metabolite hemozoin mediates the release of several potent endogenous pyrogens (TNF, MIP-1a and MIP-1b) in vitro, and altered thermoregulation in vivo. J Inflammation 45:85-96.

411. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu F-T, **Cerami A**. (1995) Identification of galectin-3 as a high affinity binding protein for advanced glycation endproducts (AGE): A new member of the AGE-receptor complex. Molecular Medicine 1(6):634-646.

412. Martiney JA, **Cerami A**, Slater AFG. (1995) Verapamil reversal of chloroquine resistance in the malaria parasite *Plasmodium falciparum* is specific for resistant parasites and independent of the weak base effect. J Biol Chem 270(38):22393-22398.

413. Berger BJ, Bendrat K, **Cerami A**. (1995) High performance liquid chromatographic analysis of biological and chemical heme polymerization. Analytical Biochemistry 231:151-156.

414. Bendrat K, Berger BJ, **Cerami A**. (1995) Haem polymerisation in malaria. Nature 378:138-139.

415. Berger BJ, Martiney J, Slater AFG, Fairlamb AH, **Cerami A**. (1995) Chloroquine resistance is not associated with drug metabolism in *Plasmodium falciparum*. J Parasitol. 81(6):1004-1008.

416. Bukrinsky M, Manogue K, **Cerami A**. (1995) Other approaches. Nature 375:195-196.

417. Vitek MP, Stopa E, Sallés FJ, Tonge P, Vlassara H, Bucala R, Manogue K, **Cerami A**. (1995) Advanced glycosylation end-products contribute to amyloidosis in Alzheimer's Disease. Research Advances in Alzheimer's Disease and Related Disorders. K. Iqbal, J.A. Mortimer, B. Winblad and H.M. Wisniewski (eds.) John Wiley & Sons Ltd.

418. Schmidtayerova H, Nottet HSLM, Nuovo G, Raabe T, Flanagan CR, Dubrovsky L, Gendelman HE, **Cerami A**, Bukrinsky M, Sherry B. (1996) HIV-1 infection alters chemokine b peptide expression in human monocytes: Implications for recruitment of leukocytes into brain and lymph nodes. Proc Natl Acad Sci USA 93:700-704.

419. Bianchi M, Bloom O, Raabe T, Cohen PS, Chesney J, Sherry B, Schmidtayerova H, Zhang X, Bukrinsky M, Ulrich P, **Cerami A**, Tracey KJ. (1996) Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylylhydrazone. J Exp Med 183:927-936.

420. Bucala R, **Cerami A**. (1996) DNA-advanced glycosylation. The Maillard Reaction: Consequences for the Chemical and Life Sciences. R. Ikan (ed.) John Wiley & Sons Ltd.

421. Martiney JA, **Cerami A**, Slater AFG. (1996) Inhibition of hemozoin formation in *Plasmodium falciparum* trophozoite extracts by heme analogs: Possible implication in the resistance to malaria conferred by the beta-thalassemia trait. Molecular Medicine 2(2):236-246.

422. Berger BJ, Dai WW, Wang H, Stark RE, **Cerami A**. (1996) Aromatic amino acid transamination and methionine recycling in trypanosomatids. Proc Natl Acad Sci USA 93:4126-4130.

423. Cockroft KM, Meistrell III M, Zimmerman GA, Risucci D, Bloom O, **Cerami A**, Tracey KJ. (1996) Cerebroprotective effects of aminoguanidine in a rodent model of stroke. Stroke 27:1393-1398.

424. Bernhagen J, Calandra T, Mitchell RA, **Cerami A**, Bucala R. (1996) Macrophage migration inhibitory factor is a novel mediator of septic shock. Proceedings of the 3rd Int'l Congress on the Immune Consequences of Trauma, Shock and Sepsis-Mechanisms and Therapeutic Approaches. E. Faist, A.E. Baue, F.W. Schildberg (eds.) 1:394-396.

425. Cohen PS, Nakshatri H, Dennis J, Caragine T, Bianchi M, **Cerami A**, Tracey KJ. (1996) CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc Natl Acad Sci USA 93:3967-3971.

426. Vasan S, Zhang Xin, Zhang Xini, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terleckyj I, Bucala R, **Cerami A**, Egan J, Ulrich P. (1996) An agent cleaving glucose-derived protein crosslinks *in vitro* and *in vivo*. Nature 382:275-278.

427. Lee AT, **Cerami A**. (1996) Glycation. Encyclopedia of Gerontology 1:605-609.

428. Berger BJ, Paciorkowski A, Suskin M, Dai WW, **Cerami A**, Ulrich P. (1996) Antimalarial activity of novel arylene bis(methylketone) compounds. J Infectious Diseases 174:659-662.

429. Popov S, Dubrovsky L, Lee MA, Pennathur S, Haffar O, Al-Abed Y, Tonge P, Ulrich P, Rexach M,

Blobel G, **Cerami A**, Bukrinsky M. (1996) Critical role of reverse transcriptase in the inhibitory mechanism of CNI-H0294 on HIV-1 nuclear translocation. *Proc Natl Acad Sci USA* 93:11859-11864.

430. Zhang M, Caragine T, Wang H, Cohen PS, Botchkina G, Soda K, Bianchi M, Ulrich P, Sherry B, **Cerami A**, Sherry B, Tracey KJ. (1997) Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: A counterregulatory mechanism that restrains the immune response. *J Exp Med* 185 (10):1759-1768.

431. Berger BJ, Suskin M, Dai WW, **Cerami A**, Ulrich P. (1997) Studies on the pharmacological properties of novel arylene bis(methylketone) compounds using solid-phase extraction and high-performance liquid chromatography. *J of Chromatography B* 691:433-440.

432. Berger BJ, Dai WW, **Cerami A**, Ulrich P. (1997) Studies on the mechanism of antimalarial action of a novel arylene bis(methylketone). *Biochemical Pharmacology* 54:739-742.

433. Paciorowski A, Dai WW, **Cerami A**, Berger BJ. (1997) Synergism of cimetidine with anti-malarial agents. *J Parasitol* 83(5):960-963.

434. Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-abed Y, Vlassara H, Bucala R, **Cerami, A**. (1997) Tobacco smoke is a source of toxic reactive glycation products. *Proc Natl Acad Sci USA* 94:13915-13920.

435. Sherry B, Zybarth G, Alfano M, Dubrovsky L, Mitchell R, Rich D, Ulrich P, Bucala R, **Cerami A**, Bukrinsky M. (1998) Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes. *Proc Natl Acad Sci USA* 95:1758-1763.

436. Wolffenbittel BHR, Boulanger CM, Crijns FRL, Huijberts MSP, Poitevin P, Swennen GNM, Vasana S, Egan JJ, Ulrich P, **Cerami A**, Levy BI. (1998) Breakers of advanced glycation endproducts restore large artery properties in experimental diabetes. *Proc Natl Acad Sci USA* 95(8):4630-4634.

437. Haffar OK, Smithgall MD, Popov S, Ulrich P, Bruce AG, Nadler SG, **Cerami A**, Bukrinsky MI. (1998) CNI-H0294, a nuclear importation inhibitor of the human immunodeficiency virus type 1 genome, abrogates virus replication in infected activated peripheral blood mononuclear cells. *Antimicrobial Agents and Chemotherapy* 42(5):1133-1138.

438. Martiney JA, Rajan AJ, Charles PC, **Cerami A**, Ulrich PC, Macphail S, Tracey KJ, Brosnan CF. (1998) Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage deactivating agent. *J Immunol* 160:5588-5595.

439. Sherry B, Espinoza M, Manogue KR, **Cerami A**. (1998) Induction of the chemokine b peptides, MIP-1a and MIP-1b, by lipopolysaccharide is differentially regulated by immunomodulatory cytokines g-IFN, IL-10, IL-4, and TGF-b. *Molecular Medicine* 4:648-657

440. Al-Abed Y, Mitsuhashi T, Hongwei L, Lawson JA, Fitzgerald GA, Founds H, Donnelly T, **Cerami A**, Ulrich P, Bucala R. (1999) Inhibition of advanced glycation endproduct formation by acetaldehyde: Role in the cardioprotective effect of ethanol. *Proc Natl Acad Sci USA* 96(5): 2385-2390.
441. Martiney JA, Ferrer AS, **Cerami A**, Dzekunov S, Roepe P. (1999) Chloroquine uptake, altered partitioning and the basis of drug resistance: Evidence for a role of chloride-dependent ionic regulation. Transport and trafficking in the malaria-infected erythrocyte. Wiley, Chichester (Novartis Foundation Symposium 226) pp. 265-280.
442. Asif M, Egan J, Vasani S, Jyothirmayi GN, Masurekar MR, Lopez S, Williams C, Torres RL, Wagle D, Ulrich P, **Cerami A**, Brines M, Regan TJ. (2000) An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness *Proc Natl Acad Sci USA* 97(6): 2809-2813.
443. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, **Cerami A**. (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. *Proc Natl Acad Sci USA* 97(19): 10526-10531.
444. Vaitkevicius, PV, Lane M, Spurgeon H, Ingram DK, Roth GS, Egan JJ, Vasani S, Wagle DR, Ulrich P, Brines M, Wuerth J-P, **Cerami A**, Lakatta EG. (2001) A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. *Proc Natl Acad Sci USA* 98(3): 1171-1175.
445. Ulrich P, **Cerami A**. (2001) Protein Glycation, Diabetes and Aging: Recent Progress in Hormone Research, 56:1-21
446. Siren A-L, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, **Cerami A**, Ehrenreich H, Ghezzi P. (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress *Proc. Natl Acad Sci USA* 98(7) 4044-4049
447. **Cerami A**, Brines M, Ghezzi P, Cerami C. (2001) Effects of epoetin alfa on the central nervous system - Seminars in Oncology 28(2) Supplement H. John W. Yarbor and Michael J. Mastrangelo (eds.) Philadelphia, PA. pp. 66-69.
448. **Cerami, A**, Ulrich P. Pharmaceutical intervention in advanced glycation end-product formation. (2001) *New Horizons in Occlusive Arterial Disease. Proceedings of the Fourth Harveian-Texan Conference: Stuttgart: Schattauer Verlag.*
449. **Cerami, A**. (2001) Beyond erythropoiesis: Novel applications for recombinant human erythropoietin. *Seminars in Hematology* 38(3) Supplement 7. Neal S. Young and Photis Beris (eds.) Philadelphia, PA. pp. 33-38.

450. Celik M, Gökmen N, Erbayraktar S, Akhisaroglu M, Konakç S, Ulukus C, Genc S, Genc K, Sagiroglu E, **Cerami A**, Brines M. (2002) Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. *Proc. Natl Acad Sci USA* 99(4) 2258-2263.

451. **Cerami A**, Brines M, Ghezzi P, Cerami C, Itri LM.(2002) Neuroprotective properties of epoetin alfa. *Nephrol Dial Transplant* 17(1): 8-12.

452. Gorio A, Gökmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, Di Giulio AM, Vardar E, **Cerami A**, Brines M.(2002) Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. *Proc Natl Acad Sci USA* 99(14): 9450-9455.

453. Junk A, Mammis A, Savitz S, Singh M, Roth S, Malhotra S, Rosenbaum P, Brines M, **Cerami A**, Rosenbaum D. (2002) Erythropoietin Administration protects retinal neurons from acute ischemia-reperfusion injury. *Proc Natl Acad Sci USA* 99(16): 10659-10664.

454. Ehrenreich H, Hasselblatt M, Lewczuk P, Dembowski C, Cepek L, Stiefel M, Rustenbeck H-H, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, DeRyck M, Itri L, Prange H, **Cerami A**, Brines M, Siren AL. (2002)Erythropoietin therapy for acute stroke is both safe and beneficial. *Molecular Medicine* 8(8): 495-505.

455. Calvillo L, Latina R, Kajstura J, Leri A, Anversa P, Ghezzi P, **Cerami A**, Brines M. (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. *Proc Natl Acad Sci USA* 100(8):4802-6.

456. Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M, Torup L, Sager T, Erbayraktar Z, Gokmen N, Yilmaz O, Ghezzi P, Villa P, Fratelli M, Casagrande S, Leist M, Helboe L, Christensen S, Geist A, Østwegaard Pedersen L, Hand C, Wuerth JP, **Cerami A**, Brines M. (2003) Asialoerythropoietin is a non- erythropoietin cytokine with broad neuroprotective activity in vivo. *Proc Natl Acad Sci* 100; 6741-6746.

457. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, **Cerami A**, Coleman T, Brines Michael, Ghezzi P. (2003) Erythropoietin Selectively Attenuates Cytokine Production and Inflammation in Cerebral Ischemia by targeting neuronal apoptosis. *J Exp Med* 198 (6) 1-7.

458. Grasso G, Sfacteria A, Brines M, **Cerami A**, Tomasello F. A New Computed-Assisted Technique for Experimental Sciatic Nerve Function Analysis. (2003) *Medical Science Monitor*10(1): BR1-3.

459. Ehrenreich H, Degner D, Melle J, Brines M, Béhé, Hasselblatt M, Woldt H, Falkai P, Knerlich F, Jacob S, von Ahsen N, Maier W, Brück W, Ruther E, **Cerami A**, Becker W, Sirén A-L. (2003) Erythropoietin: a candidate compound for neuroprotection in schizophrenia. *Molecular Psychiatry* 1-13.

460. Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggiono N, Lauria G, Borgna M, Lombardi R, Cimen B, Comelikoglu U, Kanik A, Tataroglu C, **Cerami A**, Ghezzi P. (2004) Erythropoietin both protects from and reverses experimental diabetic neuropathy. *Proc Natl Acad Sci U S A* 101(3):823-8.

461. Eid T, Brines M, **Cerami A**, Spencer DD, Kim JH, Schweitzer JS, Ottersen OP, de Lanerolle NC. (2004) Increased expression of erythropoietin receptor on blood vessels in the human epileptogenic hippocampus with sclerosis. (2004) *J Neuropathol Exp Neurol* 63(1):73-83.

462. Grasso G, Sfacteria A, **Cerami A**, Brines M. (2004) Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? *Neuroscientist* 10(2):93-8.

463. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, **Cerami A**: (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. *Proc Natl Acad Sci USA* 101(41):14907-12.

464. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Perersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokemen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, **Cerami A**, Brines M: (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. *Science* 9;305(56810):239-42.

465. Butler RN, Warner HR, Williams TF, Austas SN, Brody JA, Campisi J, **Cerami A**, Cohen G, Cristofalo VJ, Drachman DA, Finch CE, Fridovich I, Harley CB, Havlik RJ, Martin GM, Miller RA, Olshansky SJ, Pereira-Smith OM, Smith JR, Sprott RL, West MD, Wilmoth JR, Wright WE: (2004) The aging factor in health and disease: the promise of basic research on aging. *Aging Clin Exp Res.* 16(2):104-11

466. Ghezzi P, **Cerami A**. (2005) Tumor necrosis factor as a pharmacological target. *Mol. Biotechnol.* 31(3):239-44.

467. Gorio A, Madaschi L, Di Stefano B, Carelli S, Di Giulio AM, De Biasi S, Coleman T, **Cerami A**, Brines M. (2005) Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. *Proc Natl Acad Sci U S A* 102(45):16379-16384.

468. Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, Doni M, Mengozzi M, Tonelli R, Ghezzi P, Coleman T, Brines M, **Cerami A**, Latini R: (2005) A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. *Proc Natl Acad Sci USA* 102(6):2046-51.

469. Brines, M, **Cerami, A** (2005) Emerging biological roles for erythropoietin in the nervous system. *Nature Review Neurosci.* 6(6)484-494.

470. Savino C, Pedotti R, Baggi F, Ubiali F, Gallo B, Nava S, Bigini P, Barbera S, Fumagalli E, Mennini T, Vezzani A, Rizzi M, Coleman T, **Cerami A**, Brines M, Ghezzi P, Bianchi R: (2006) Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. *J Neuroimmunol* 172(1-2):27-37.

471. Coleman T, Westenfelder C, Tögel FE, Yang Y, Hu Z, Swenson L, Leuvenink HG, Ploeg RJ, d'Uscio LV, Katusic ZS, Ghezzi P, Zanetti A, Kaushansky K, Fox NE, **Cerami A**, Brines M: (2006) Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. *Proc Natl Acad Sci U S A* 11;103(15):5965-70.

472. Brines M, **Cerami A**: Tissue-protective cytokines in spinal cord injury: Challenges for a novel neuroprotective strategy, in *Erythropoietin and the Nervous System: Novel Therapeutic Options for Neuroprotection*, edited by Hoke A, New York, Springer, (2006), pp 147-164

473. Bianchi R, Brines M, Lauria G, Savino C, Gilardini A, Nicolini G, Rodriguez-Menendez V, Oggioni N, Canta A, Penza P, Lombardi R, Minoia C, Ronchi A, **Cerami A**, Ghezzi P, Cavaletti G: (2006) Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. *Clin Cancer Res* 12(8):2607-2612.

474. Erbayraktar S, de Lanerolle N, de Lotbinière A, Knisely JP, Erbayraktar Z, Yilmaz O, **Cerami A**, Coleman T, Brines M: (2006) Carbamylated erythropoietin reduces radiosurgically-induced brain injury. *Mol Med* 12(4-6):74-80.

475. Grasso G, Sfacteria A, Erbayraktar S, Passalacqua M, Meli F, Gokmen N, Yilmaz O, La Torre D, Buemi M, Iacopino DG, Coleman T, **Cerami A**, Brines M, Tomasello: (2006) Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative. *J Neurosurg Spine*. 4(4):310-8.

476. Brines M, **Cerami A**: (2006) Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. *Kidney Int*. 70(2):246-50.

477. Mennini T, De Paola M, Bigini P, Mastrotto C, Fumagalli E, Barbera S, Mengozzi M, Viviani B, Corsini E, Marinovich M, Torup L, van Beek J, Leist M, Brines M, **Cerami A**, Ghezzi P: (2006) Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. *Mol. Med*. 12(7-8):153-60.

478. Fantacci M, Bianciardi P, Caretti A, Coleman T, **Cerami A**, Brines M, Samaja M: (2006) Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. *Proc Natl Acad Sci USA* 14;103(46):17531-6.

479. Villa P, van Beek J, Larsen AK, Gerwien J, Christensen S, **Cerami A**, Brines M, Lesit M, Ghezzi P, Torup L: (2007) Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. *J Cereb Blood Flow Metab*

27(3):552-63.

480. Taoufik E, Petit E, Divoux D, Tseveleki V, Mengozzi M, Roberts ML, Valable S, Ghezzi P, Quackenbush J, Brines M, **Cerami A**, Probert L: (2008) TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. *Proc Natl Acad Sci USA*. 105(16):6185-90.

481. Beutler B, Milsark IW, **Cerami A**: (2008) Passive immunization against cachectin/ tumor necrosis factor protects mice from lethal effect of endotoxin. *Science* 1985, 229: 869-871 Classical Article. *J Immunol*. 181(1):7-9.

482. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand C, Xie QW, Coleman T, **Cerami A**: (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. *Proc Natl Acad Sci USA*. 105(31):19025-30.

483. Brines M, **Cerami A**: (2008) Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. *J Intern Med*. 264(5):405-32.

484. Gunnarson E, Song Y, Kowalewski JM, Brismar H, Brines M, **Cerami A**, Andersson U, Zelenina M, Aperia A: (2009) Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection. *Proc Natl Acad Sci USA* 106(5):1602-7.

485. Erbayraktar Z, Erbayraktar S, Yilmaz O, **Cerami A**, Coleman T, Brines M: (2009) Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing. *Mol Med*. 15(7-8):235-41.

486. **Cerami A**. The value of failure: the discovery of TNF and its natural inhibitor erythropoietin (Key Symposium). *J Intern Med* 2011; 268: 8-15.

487. Ahmet I, Tae HJ, Juhaszova M, Riordon DR, Boheler KR, Sollott SJ, Brines M, **Cerami A**, Lakatta EG, Talan MI. (2011). A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage. *Mol Med*. 17:194-200.

488. Polgárová K, Lüthje P, **Cerami A**, Brauner A. (2011). The erythropoietin analogue ARA290 modulates the innate immune response and reduces *Escherichia coli* invasion into urothelial cells. *FEMS Immunol Med Microbiol* 62:190-196.

489. Swartjes M, Morariu A, Niesters M, Brines M, **Cerami A**, Aarts L, Dahan A. (2011). ARA290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-term Relief of Neuropathic Pain: An Experimental Study in Rats and β -Common Receptor Knockout Mice. *Anesthesiology*. 2011 Aug 25. [Epub ahead of print].